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ABSTRACT 
DLBCL is the most common lymphoma subtype occurring in older populations as well as 
in younger HIV infected patients. The current treatment options for DLBCL are effective 
for most patients yet the relapse rate is high. While many biomarkers for DLBCL exist, 
they are not in clinical use due to low sensitivity and specificity. In addition, these 
biomarkers have not been studied in the HIV context. Therefore, the identification of new 
biomarkers for HIV negative and HIV positive DLBCL, may lead to a better 
understanding of the disease pathology and better therapeutic design. 
Initially differences in the clinicopathological features between HIV negative and HIV 
positive DLBCL patients were determined by conducting a retrospective study of patients 
treated at GSH. Subsequent to this, potential protein biomarkers for DLBCL were 
determined using MALDI imaging mass spectrometry (IMS) and characterised using LC-
MS.  The expression of one of the biomarkers, heat shock protein (Hsp) 70, was 
confirmed on a separate cohort of samples using immunohistochemistry. 
Our results indicate that the clinicopathological features for HIV negative and HIV 
positive DLBCL are similar except for median age, and frequency of elevated LDH 
levels.  Several clinicopathological factors were prognostic for all DLBCL cases 
including age, gender, stage and bone marrow involvement. In addition, tumour 
extranodal site was also a prognostic indicator for the HIV negative cohort. The 
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biomarkers identified in the study consisted of four protein clusters including glycolytic 
enzymes, ribosomal proteins, histones and collagen. These proteins could differentiate 
between control and tumour tissue, and the DLBCL subtypes in both cohorts.  The 
majority (41/52) of samples in the confirmation cohort were negative for Hsp70 
expression. The HIV positive DLBCL cases had a higher percentage of cases expressing 
Hsp70 than their HIV negative counterparts. The non-GC subtype also frequently 
overexpressed Hsp70, confirming MALDI IMS data. Expression of Hsp70 correlated 
with poor outcome in the HIV negative cohort.  
 
In conclusion, this study identified potential biomarkers for HIV negative and HIV 
positive DLBCL from both clinical and molecular sources. These may be used as 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 BACKGROUND 
1.1.1 B lymphocyte development 
 
There are two types of lymphocytes include T lymphocytes and B lymphocytes. The 
former is derived from the thymus while the latter is derived from the bone marrow.  The 
development of B lymphocytes begins in the bone marrow followed by maturation in 
secondary lymphoid tissue (Lebien & Tedder 2008). Development begins with the 
common lymphocyte progenitor (CLP) differentiating into pre B- cells expressing 
surrogate L chains (SLC)- a pre B- cell receptor (BCR) (Bankovich et al. 2007). 
Maturation into BCR occurs through signalling induced by ligand independent 
oligomerization of two pre-BCR (Bankovich et al. 2007). The differentiation stages 
occurring in secondary lymphoid tissue are antigen dependent; giving rise to either 
antibody producing plasma cells or memory B- cells (Lebien & Tedder 2008).  
 
1.1.2 B- cell maturation 
 
Germinal centres develop in lymph nodes in response to antigen binding to the BCR 
expressed by B lymphocytes (Gatto & Brink 2012). Germinal centres contain the B- cell 
rich dark zone and the follicular dendritic cells (FDC) and follicular helper T- cells (TFH) 
cell rich light zone (Figure 1.1). Germinal centres form when naive B- cells, upon antigen 
binding, are co-activated outside follicles in the T- cell rich zone (MacLennan 
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1994)(Figure 1.1). The movement of B- cells to the T cell rich zone is mediated by the 




Figure 1.1: The structure of the germinal centre in lymph nodes. The dark zone (DZ) is 
made up of a high density of B- cells while the light zone (LZ) has fewer numbers with a 
meshwork of follicular dendritic cells (FDC) (Gatto & Brink 2012). 
 
Following activation by TFH cells, B-cells undergo rapid expansion; somatic 
hypermutation (SHM) of the IG genes; and class switch recombination (CSR) at the IgH 
locus in the dark zone (Lebien & Tedder 2008). They are now known as centroblasts. 
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Upon antigen stimulation, the centroblasts migrate to the light zone and become 
centrocytes. They are now in activated apoptosis and have high levels of BCL6. They 
compete for the CD 40L expressed on TFH cells and FDCs in a process called ‘selection’ 
enabling them to survive (Vinuesa 2013). A subset of B- cells resume the dark zone 
process in order to improve antigen selection and this may be mediated by the MYC 
protein (Karube & Campo 2015). Upon stimulation the centrocytes exit the germinal 
centre as an antibody producing plasma cell or a memory B- cell.  
1.1.3 B- cell abnormalities 
 
Irregularities in B-cell development can give rise to immunodeficiencies, leukaemia, 
lymphomas and autoimmune diseases (Kuppers et al. 1999). Autoimmune diseases such 
as rheumatoid arthritis and systemic lupus erythematosus are a result of  failure to tolerate 
self-antigens by B-cells (Hampe 2012). Approximately two thirds of B- cells are self-
reactive and are subjected to three distinct tolerance mechanisms, including, clonal 
deletion, receptor editing and anergy (Tsubata 2005). Malignancies of B- cells arise at 
different stages of B- cell development resulting in a wide range of morphologic and 
clinical presentations (Longo 2010). They can present as either leukaemia or lymphoma 




1.1.4 B-cell lymphomas form at different stages of B- cell development 
 
The majority B- cell non-Hodgkin lymphomas, including Burkitt lymphoma, follicular 
lymphoma and diffuse large B- cell lymphoma (DLBCL) are derived from GC B- cells 
(Kuppers et al. 1999; Stevenson & et al 2001). Burkitt lymphomas are derived from the 
dark zone B- cells (Dave et al. 2006), whereas follicular lymphoma and DLBCLs 
correspond to B- cells arrested at various stages of GC development (Figure 1.2) 
(Alizadeh et al. 2000). In particular, follicular lymphoma and the GC B- cell (GCB)-like 
subtype of DLBCL resemble light zone B- cells, whereas activated B cell (ABC)-like 
DLBCLs derive from GC cells arrested during the early stages of plasma cell 




Figure 1.2: The origin of B- cell malignancies. Various types of NHL subtypes arise from 
B- cells arrested at different stages of B-cell development. Burkitt lymphoma arises from
the dark zone while follicular lymphoma and the germinal centre subtype of diffuse large 




Lymphoma is an uncontrollable growth of lymphocytes in the lymphoid system (Almieda 
& Barry 2009).  There are two types of lymphoma: Hodgkin’s lymphoma (HL) and non-
Hodgkin’s lymphoma (NHL).  HL is mainly characterised by the presence of Reed- 
Sternberg giant cells.  NHL on the other hand is composed of a wide spectrum of disease 
differing in their pathobiology and therapy. The majority of NHLs originate from B-cells, 
with diffuse large B- cell lymphoma (DLBCL) making upto 40% (Contran et al. 1989). In 
2012, there were approximately 400000 people diagnosed with NHL globally (Ferlay et 
al. 2012). To add to the burden of cancer population, HIV infection and AIDS increases 
the risk of developing NHL (Golematis & DeVita Jr 1996). NHL treatment currently 
involves the use of toxic, high dose chemotherapy, irrespective of HIV status or subtype. 
The aforementioned therapy has a high relapse rate due to the heterogeneity inherent 
within the disease. Therefore, there is need for alternative treatment regiments that are 
less toxic and tailor-made for a specific cancer. 
Biomarkers are “cellular, biochemical or molecular alterations that are measurable in 
biological media such as tissues, cells or fluids” (Hulka 1990).  Cancer biomarkers can 
be stratified into three categories: diagnostic biomarkers; prognostic biomarkers and 
predictive biomarkers (Hamdan 2007). Since proteins are the effectors of all biological 
processes, they have been the main target for biomarker discovery drives. Therefore, 
there is substantial interest in applying proteomics technologies towards the identification 
of disease biomarkers. 
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Proteomics involves the identification and characterization of a complete set of 
proteins/peptides at a given time (Chandramouli & Qian 2009).  Mass spectrometry (MS) 
has the potential to yield comprehensive profiles of peptides and proteins in biological 
tissues without carrying out protein separations by gel electrophoresis (Zhou & Veenstra 
2013).  This type of approach is highly suited for biomarker identification due to reduced 
sample concentration requirements and high throughput (Han 2011). The most commonly 
used platforms for MS analysis are matrix assisted laser desorption/ionisation (MALDI) 
and electrospray ionisation (ESI). MALDI is frequently combined with time of flight 
(TOF) mass analysers while ESI is joined to liquid chromatography mass spectrometers 
(LC-MS) (Khadir & Tiss 2013). There are various sample types that can be used for 
protein extraction and analysis. One of the untapped tissue treasures include formalin 
fixed paraffin embedded (FFPE) tissues. FFPE tissue blocks have a history of being 
excellent substrates for morphological and immunological studies in pathology 
(Magdeldin & Yamamoto 2012). In addition, emerging studies show that it is possible to 
use FFPE tissues in mass spectrometry analyses; particularly in biomarker identification 
investigations (Craven et al. 2013; Sousa et al. 2012; Takadate et al. 2013).  
This literature review will cover the scope of protein biomarkers characterised for HIV 
related and non-HIV related DLBCL. Following the literature review, the thesis will 
continue onto two chapters of results, each containing a brief discussion. These will then 
be followed by a final conclusion.  
The first chapter of the results will compare the clinical characteristics of HIV and non 
HIV related DLBCL patients treated at Groote Schuur Hospital (GSH). The second 
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chapter will compare the differences in protein expression profiles between the two study 
groups. The expression of one of the differentially expressed protein will be confirmed 






1.3.1 The incidence of lymphomas 
 
Lymphomas and leukaemia’s are a part of the broader group of tumours of the 
hematopoietic and lymphoid tissues (Nayak et al. 2013). Lymphoma is the name applied 
to a group of blood cell tumours that develop from lymphatic cells (Müller et al. 2005; 
Hennessy et al. 2004). In 2012, statistics showed that lymphomas developed in 450,000 
people worldwide and caused over 200,000 deaths (Ferlay et al. 2012). Lymphomas 
consist of 3–4% of all cancers, making them the seventh-most common form of cancer. 
The two main categories of lymphomas are Hodgkin lymphomas and the non-Hodgkin 
lymphomas, the majority being NHL (Jaffe et al. 2008; Aisenberg 2000). Symptoms of 
lymphoma may include the so called ‘B’ symptoms which consist of fever, sweating, and 
weight loss (Levine 1992).  
 
1.3.2 Differences between lymphoma subtypes 
 
Hodgkin lymphomas differ from non- Hodgkin lymphomas in several ways. The age 
distribution of HL is bimodal occurring in young adults as well as in the fifth decade 
while in NHL, the age distribution is unimodal peaking in the sixth decade (Rosolen et al. 
2000; Giunti et al. 2002). The ‘B’ symptoms are more common in HL than in NHL. 
Initial presentation of HL is usually localised nodal disease in contrast to the generalised 
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nodal disease with extranodal presentation observed in NHL (Rosenberg & Kaplan 
1970). HL are characterised by the presence of Reed-Sternberg cells while NHL mostly 
originate from B cells but NHL can also arise from T cell and natural killer cells (Giunti 
et al. 2002; Hennessy et al. 2004). Some NHL subtypes are associated with specific 
chromosomal translocations of proto-oncogenes into either the immunoglobulin gene or 
other genes (Rosolen et al. 2000; Vega & Medeiros 2003); while there are no known 
specific genetic defects in HL (Hudnall 2011) 
1.3.3 Non-Hodgkin’s lymphoma 
 
Non-Hodgkin lymphomas are a group of neoplasms whose clinical presentation and 
natural history are more variable than in Hodgkin’s lymphoma (Hoffbrand et al. 2006; 
Nayak et al. 2013). There are more than sixty subgroups of NHL, some having more than 
one subtype(Campo et al. 2011). Thirty percent of NHLs present in extranodal sites with 
the gastrointestinal tract being the most frequent site followed by the head and neck 
region constituting 11-33% of the cases (Nayak et al. 2013). A number of classification 
systems have been developed to categorize NHL. Early classification systems such as the 
Rappaport (1966) were based exclusively on lymph node architecture and cell 
morphology (Hu et al. 2011; Garvin et al. 1980). However, increased understanding of 
lymphocyte biology led to the Kiel and Lukes-Collins classification system in 1974, the 
Working Formulation for Clinical Usage (WF) in 1982 and the revised American 
European lymphoma (REAL) system in 1994 (Hoffbrand et al. 2006). The current World 
Health Organisation (WHO) discouraged the use of subdividing lymphomas on the basis 
 
 11 
of histological appearance only to ‘distinct syndromes each with a characteristic 
morphological, immunophenotypic, genetic and clinical features’(Jaffe 2009).  
 
 
1.3.4 Diffuse large B- cell lymphoma 
 
Diffuse large B- cell lymphoma (DLBCL) is the most commonly diagnosed NHL 
subgroup, comprising of more than a third of NHL cases in South Africa(Lossos & 
Morgensztern 2006; Tilly & Dreyling 2009; Patel et al. 2015). It is composed of a 
heterogeneous group with different morphological, histopathological and genetic 
subtypes (Klapper et al. 2012).  According to the WHO classification, diffuse large B-cell 
lymphoma is subdivided into several subtypes as follows: DLBCL, NOS; T cell/ 
histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; 
Epstein Barr positive DLBCL of the elderly (Jaffe 2009).  
 
1.3.4.1 Morphological variants of DLBCL 
DLBCL is histologically characterised by a diffuse proliferation of large neoplastic B 
lymphoid cells with a nuclear size equal to or exceeding that of normal histiocyte nuclei 
(Campo et al. 2011). In most cases, these neoplastic cells morphologically resemble 
either centroblasts or immunoblasts, and usually both are present in the same tumour 
(Dominis et al. 2002). There are three morphological variants of DLBCL, namely: 
centroblastic, immunoblastic and anaplastic (Figure 1.3) (Xie et al. 2015). The 
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centroblastic variant contains medium to large lymphoid cells with vesicular nuclei, 
irregular nuclear membrane and multiple nucleoli(Hunt & Reichard 2008).  In the 
immunoblastic variant, greater than 90% of the cells contain a single, centrally located 
nucleolus and appreciable amount of cytoplasm (Hu et al. 2011). The anaplastic variant is 
a rare morphological variant of DLBCL characterized by the presence of large cells with 
bizarre pleomorphic nuclei that may resemble Reed –Sternberg cells and tumour cells of 
anaplastic large cell lymphoma (ALCL), thereby rendering them diagnostically 
challenging (Mona et al. 2014). Centroblastic lymphoma is the most common subtype 
with better prognosis when compared with immunoblastic and anaplastic variants of 








Figure 1.3: H&E sections of the morphological variants of DLBCL(Modified from Hunt 
& Reichard 2008). (A) The centroblastic variant  have large blast cells with vesicular 
nuclei, irregular nuclear membrane and multiple nucleoli (X600).(B) The immunoblastic 
variant contains numerous blast cells with prominent single  nucleolus, regular nuclear 
membrane and vesicular chromatin (X400). 
 
 
1.3.4.2 Genetic variants of DLBCL 
DLBCL consists of three genetic variants that point to the origin of the tumour; the so 
called ‘cell of origin’ (COO). The study by Alizadeh et al (2000) was the first to suggest 
that lymphomas retain the gene expression of the COO (Alizadeh et al. 2000; Xie et al. 
2015). This suggests that different types of DLBCL arise from different stages of B cell 
differentiation (Lossos et al. 2000).These genetic DLBCL subtypes are not related to any 
of the morphological subtypes of DLBCL (Rosenwald et al. 2002). The study used gene 
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expression profiling (GEP) to classify DLBCL into two groups (Alizadeh et al. 2000).The 
first group had a high expression of genes expressed in the B- cells of the germinal centre 
and was named the  GCB type. The second group had a genetic signature similar to 
activated B cells and was named  ABC type (Alizadeh et al. 2000). The classification 
demonstrated prognostic significance with statistically different 5 year survival outcomes 
(GCB- 76% vs. ABC- 16%) (Alizadeh et al. 2000). A third group named ‘type 3’ was 
identified by Rosenwald et al (2002) and his colleagues in 2002 (Rosenwald et al. 2002).  
This subgroup was heterogeneous, not well defined and had similar prognosis to that of 
the ABC subtype (Rosenwald et al. 2002). The genetic variants of DLBCL also have 
differing genetic aberrations and molecular pathways. The GCB type is frequently 
associated with the t(14;18) (q32;q21) chromosomal aberration as well as gains at 7q, 
deletion of the tumour suppressor PTEN and losses at 16q (Barrans et al. 2003; Iqbal et 
al. 2004; Lenz et al. 2008; Guo et al. 2014). However, the non-GCB type is defined by 
gains at11q24.3 and 3q13.2 (Guo et al. 2014)as well as a constitutively active NF-kB
pathway (Davis et al. 2001). 
1.3.4.3 Immunohistological algorithms for COO classification 
The GEP technology used in classifying DLBCL is expensive and not user friendly thus 
making it unsuitable for regular diagnostic practise (Hans et al. 2004). This feature gave 
rise to the search for protein markers that define each genetic DLBCL subtype that can be 
detected immunohistologically. A number of immunohistochemical algorithms have been 
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developed to stratify patients according to their COO type, using various markers (Hans 
et al. 2004; Muris et al. 2006; Natkunam et al. 2001; Choi et al. 2009; Meyer et al. 2010). 
These algorithms target proteins whose genes have been shown to be highly expressed in 
either GCB or ABC subtypes (Meyer et al. 2011). Proteins that are highly expressed in 
GCB include CD10, BCL6 and GCET1. Those highly expressed in ABC include: 
MUM1, cyclin D, CD44 and FOXP1 (Meyer et al. 2011; Dunleavy et al. 2013). The 
algorithms developed by Hans et al (2004) and Choi et al (2009) are the only ones that 
were highly correlated with GEP data. They were able to correctly classify samples 
according to GEP data by determining the protein expression of the genes that are 
commonly overexpressed in each subtype. The Hans algorithm uses three markers 
(CD10, BCL6 and MUM1), while the Choi algorithm uses five markers (GCET1, CD10, 
MUM1, BCL6, FOXP1) (Hans et al. 2004; Choi et al. 2009). The other algorithms were 
not correlated with GEP data and relied on prognostic differences between the groups 
(Muris et al. 2006; Natkunam et al. 2001; Meyer et al. 2010).  Both the Hans and Choi 
algorithms show high (above 80%) concordance with GEP data (Choi et al. 2009). 
However the Choi algorithm is not user friendly and some of the markers used are not 






1.4. HUMAN IMMUNODEFICIENCY VIRUS INFECTION /ACQUIRED IMMUNE 
DEFICIENCY SYNDROME (HIV/AIDS) 
 
The human immunodeficiency virus (HIV) belongs to the lentivirus genus of the 
retroviridae family (Coffin JM, Hughes SH 1997). HIV infects the immune T 
lymphocytes using receptors that these cells express for entry (Wilen et al. 2012).  HIV 
infection progresses in stages and culminates in acquired immune deficiency syndrome 
(AIDS). The following criteria are required to diagnose an infected patient as having 
AIDS: a CD4 count of less than 200 cells/ mm3 and/or presence of AIDS defining illness 
(World Health Organisation 2007).  The AIDS defining illnesses encompass a spectrum 
of diseases which can be broadly classified as opportunistic infections and AIDS related 
malignancies (Deeks et al. 2013).  AIDS related malignancies include Kaposi sarcoma 
(KS), NHL and invasive cervical cancer (Bower et al. 2006; Centers for disease control 
1987). 
 
Treatment for HIV infection involves targeting the HIV virus at various points of the life 
cycle. There are various drugs available that affect the HIV life cycle including: protease 
inhibitors; chemokine receptor antagonist; integration inhibitors; reverse transcription 
inhibitors; and fusion inhibitors (Maartens et al. 2014). The current therapeutic strategy 
(highly active anti-retroviral therapy [HAART]) involves the use of anti-retroviral drugs 





1.4.1 Epidemiology of HIV/AIDS in Southern Africa 
 
In 2013, there were 24.7 million people living with HIV in Sub-Saharan Africa. This 
amounted to 71% of the global population (UNAIDS 2015). South Africa has one of the 
highest HIV prevalence rates in Sub-Saharan Africa which accounted for 25 % of the 
global figures in 2013 (UNAIDS 2015).  The number of people living with HIV in 2014 
was  5.51 million (Shisana et al. 2012). The higher prevalence rate may be partly due to 
infected people living longer because of access to HAART, thus increasing the disease 
burden even if new infections are on the decrease (Shisana et al. 2012). In South Africa 
there are currently 2.6 million people receiving HAART treatment (UNAIDS 2015).   
 
1.4.2 The role of HIV in lymphomagenesis 
 
Currently, there is little understanding of how HIV induces lymphomagenesis in AIDS 
related lymphomas, which are predominantly of B-cell origin (Monroe & Silberstein 
1995). There are two main factors that play a role in HIV lymphomagenesis: cellular 
immunodeficiency and oncogenic viruses (Besson & Raphaël 2003). The HIV-associated 
CD4+ T cellular depletion leads to the increase of Epstein Barr virus (EBV) infected B-
cells and to the decrease of antitumor immunity. The EBV oncogenic virus is frequently 
associated with HIV related NHL. Clonal EBV genome is found in lymphoma cells in 30 
to 70% of cases of HIV-related NHL. It expresses oncogenic proteins including Latent 
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membrane protein 1(LMP-1) which behaves like an activated CD40 receptor. LMP-1 
induces the expression of intracellular genes which stimulate cell growth and inhibit 
apoptosis (Besson & Raphaël 2003). In addition the increased production of B-cell 
stimulating cytokines such as IL-6 andIL-10 further promote lymphomagenesis 
(Pantanowitz et al. 2015). 
 
1.5. HIV/AIDS RELATED LYMPHOMAS 
 
AIDS related lymphomas (ARL) are frequently of B-cell phenotype and can be divided 
into three categories: lymphomas occurring in immunocompetent patients; lymphomas 
occurring only in HIV infected patients; and lymphomas occurring in other 
immunodeficient states (Pantanowitz et al. 2015; Vishnu & Aboulafia 2012). DLBCL 
and Burkitt lymphoma (BL) are the most common lymphoma subtypes seen in HIV 
infected patients also occurring in immunocompetent patients (Wiggill et al. 2013). ARL 
also commonly occur as ‘grey zone’ lymphomas which are intermediates between 
lymphoma subtypes, such as the lymphoma intermediate between BL and DLBCL 
subtype (Tirelli et al. 2000). In general, HIV-related lymphomas manifest late during 
HIV infection. However, these lymphomas can arise in patients with any CD4 count 
(Akanmu 2006). BL frequently occurs in patients with relatively high CD4counts (>200 
cells/mm3), whereas primary central nervous system lymphoma (PCNSL) and DLBCL 
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are more likely to be seen in advanced stages of immune deficiency (CD4 <50 cells/mm3) 
(Biggar et al. 2007; Pantanowitz et al. 2015).  
 
1.5.1 Risk factors for AIDS related lymphoma 
 
The relative risk of acquiring ARL increases 600 fold in patients diagnosed with AIDS 
(Levine et al. 2001).Epidemiologic studies have failed to identify major environmental 
factors associated with the development of lymphoma among HIV-infected individuals 
(Levine et al. 2001)However, genetic and host factors have been shown to influence the 
development of AIDS related lymphoma. Whilst a decreasing HIV viral load and 
increasing CD4 count are protective (Bohlius et al. 2009), older individuals (> 37years), 
the lowest CD4 cell count and a prior AIDS diagnosis have been identified as risk factors 
for developing ARL (Bohlius et al. 2009). In addition, longer periods of 
immunosuppression and uncontrolled viral loads have also been identified as risk factors 







The human genome is made up of 26000–31000 genes (Baltimore 2001). However, the 
protein products are in the range of 2-4 million due to splice variants and 
posttranslational modifications (PTMs) which include glycosylation, phosphorylation, 
and ubiquitination (Milo 2013; Hirsch et al. 2004).  Moreover, the proteomes of cells, 
tissues, and body fluids are complex and display a wide dynamic range of proteins 
concentration (Chandramouli & Qian 2009). Proteomics involves the identification and 
characterization of a complete set of proteins present in a cell, organ, or organism at a 
given time (Chandramouli & Qian 2009).  In general, proteomic techniques have 
numerous applications including protein profiling, expression analysis, identification of 
PTMs, and protein–protein interactions (Monti et al. 2005; Shiio & Aebersold 2006).  
 
1.6.1 Mass spectrometry in proteomics 
 
Initial approaches to investigate the proteome of cell lysates and body fluids were 
performed using 2D polyacrylamide gel electrophoresis (2D-PAGE) (Hirsch et al. 2004). 
MS is at the heart of virtually all proteomics experiments as it provides the key tools for 
the analysis of proteins (Guerrera & Kleiner). Mass spectrometers consist of three basic 
components: an ion source, a mass analyser, and an ion detector. MS measurements are 
carried out on ionised analytes in the gaseous phase, requiring a method to transfer 
molecules from solution or solid phase into this state. The two most commonly used 
 
 21 
techniques for ionisation are matrix assisted laser desorption/ionisation (MALDI) and 
electrospray ionisation (ESI). MALDI and ESI are both soft ionisation techniques in 
which ions are created with low internal energies and thus undergo little fragmentation 
(Karas et al. 1987; Nguyen & Fenn 2007). After ionization, the sample ions reach the 
mass analyser which separates ions by their mass-to-charge (m/z) ratios. In proteomics 
research, four basic types of mass analysers are currently being used: time-of-flight 
(TOF), ion trap, quadrupole, and Fourier transform ion cyclotron resonance (FTICR) 
analysers (Han et al. 2008).  MALDI is usually coupled to TOF analysers, which separate 
ions according to their flight time down a field-free tube (Calderaro et al. 2014). The 
ions’ time-of-flight is directly related to their m/z values and thus a mass spectrum can be 
acquired.  ESI is most frequently coupled to ion traps where the ions are first captured in 
the centre of the device for a certain time interval, followed by scanning from the trap to 
the detector.  This type of trap allows the detection of mass and sequence data (Banerjee 
& Mazumdar 2012).  
 
1.6.2 MALDI mass spectrometry 
 
In MALDI, small volumes of samples are co-crystallised with an equal volume of organic 
matrix on a metal target. A pulsed laser is used to excite the matrix, which causes rapid 
thermal heating of the molecules and eventually desorption of ions into the gas phase 
(Karas et al. 1987). MALDI produces packets of ions rather than a continuous beam 
because of the usage of a pulsed laser, therefore, it is most often coupled to a mass 
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analyser that can measure either a complete mass spectrum without scanning a mass 
range or trap all the ions for subsequent mass analysis (Calderaro et al. 2014).  It is the 
most commonly used technique because of the generation of singly charged ions, low 
concentration of sample required, simple preparation method, and the ability to analyse 
complex mixtures (Hirsch et al. 2004; Chung et al. 2007).  Limitations of the technology 
include poor mass resolution of signals above m/z 50,000, the ionization of the most 
abundant proteins, lack of reproducibility and the fact that approximately 90% of the 





1.6.3 MALDI imaging mass spectrometry 
 
An adaptation of the MALDI technique-MALDI imaging mass spectrometry (IMS) is 
used in profiling and imaging of proteins directly from tissue sections (Caprioli et al. 
1997). The choice between profiling and imaging proteins depends on the overall 
experimental objectives. Using tissue profiling methodology, the matrix is deposited in 
discrete spots on regions of interest on a tissue section. Mass signals amounting to 100 
laser shots per spot are detected in m/z 500-25000 range (Balluff et al. 2011).  The mass 
profiles between defined areas of the tissue can then be compared.  During an imaging 
experiment, a tissue section is uniformly coated with matrix solution so that protein 
profiles can be acquired over the entire area (Walch et al. 2008). Mass spectrometry data 
are acquired using a pattern of laser spots.  The distance between spots are fixed and 
depends on the resolution, typically ranging from 25 to 200 µm. The number of laser 
shots per spot is predetermined and is usually 20–50 shots are recorded (Cornett et al. 
2007). A two dimensional ion density image can be reconstructed from the intensity of a 






1.6.4 FFPE tissues for MALDI IMS 
 
Formalin fixation paraffin embedding is a preservation method with a long history in 
pathology with millions of clinical samples available in biobanks around the world 
(Eriksson et al. 2013). The formalin fixation caused protein-protein crosslinking as well 
as nucleic acid-protein crosslinking, thus preserving the integrity of the tissue (Sompuram 
et al. 2004). However, the formalin also causes the degradation and modification of 
nucleic acid and proteins (Nam et al. 2014). Despite this, these types of tissues have 
become invaluable in the process of biomarker identification due to the clinical data 
accompanying the tissue sample. Therefore, various sample preparation methods have 
been developed for reversing the crosslinking process and accessing the proteins stored in 
these tissues. In MALDI IMS, these include the use of in situ trypsin digestion (Lemaire 
et al. 2007) step or an antigen retrieval step with a selected buffer (Ronci et al. 2008; 
Casadonte & Caprioli 2011; Gustafsson et al. 2010) prior to digestion.  Although the 
latter protocol produces enhanced signal (Ronci et al. 2008), there is an introduction of 
bias towards the types of proteins ‘unlocked’ since the buffer used  is not constant and 







Biomarkers are molecular indicators of a biological status, and as biochemical species 
can be assayed to evaluate the presence of cancer and therapeutic interventions (Tainsky 
2009). Cancer biomarkers are discovered and utilized with a specific purpose including 
(a) early detection of cancer, (b) diagnosis, (c) prognosis, (d) response to anticancer 
therapies or (e) cancer recurrence (Tainsky 2009).  Numerous biomarkers have been 
identified thus far (Geisler et al. 2015). However, these have failed to be implemented in 
clinical practice because they failed to meet the high specificity and sensitivity criteria for 
clinical use. Therefore, panel biomarkers are expected to be more specific and sensitive 
for a particular cancer.  
Biomarker identification workflow involves three stages: discovery phase, verification 
phase, and validation phase. The discovery phase can be done using two approaches. The 
first approach is knowledge based, where a biomarker is chosen using known molecular 
mechanisms of the disease. The second approach is untargeted and a biomarker is chosen 
from the differentially expressed proteins between two groups (Frantzi et al. 2014). The 
verifications phase seeks to confirm the presence and levels of the candidate biomarker. 
The validation phase evaluates the clinical utility and performance of the candidate 





1.7.1 Biomarkers for DLBCL 
Biomarkers may originate from three main sources within cells: nucleic acids, proteins 
and metabolites (Tainsky 2009). 
1.7.2 International prognostic index (IPI) 
The International Prognostic Index (IPI), although not a biomarker, is the gold standard 
used for predicting the outcome for patients with NHL and is therefore a clinical 
surrogate for biomarkers (Banham et al. 2005). The IPI is based on a combined score of 
five clinical parameters (age, performance status [PS], Ann Arbor stage, extranodal 
involvement, and lactate dehydrogenase [LDH] level (Zhou et al. 2014). It only reflects 
tumour and host status biology but this alone cannot accurately predict treatment outcome 
for individual patients (Xie et al. 2014). Therefore, there is a need for additional methods 
or markers to identify high-risk patients  that can benefit from targeted therapy (Banham 
et al. 2005). 
1.7.3 Biomarkers for DLBCL independent of the IPI 
There are many individual prognostic biomarkers that have been shown to be significance 
in DLBCL. These belong to a variety of cell processes such as cell cycle regulators, 
apoptotic proteins, and proteins involved in B cell differentiation (Lossos & 
Morgensztern 2006). Below, we will focus on some of the frequently appearing in 
literature and form part of the clinical diagnostic process.  
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1.7.3.1 Ki-67 
Ki-67 is a nuclear protein that is synthesized at the beginning of cell proliferation and is 
expressed throughout the active part of the cell cycle (He et al. 2014). Its expression is 
detected immunohistochemically by dividing the number of Ki-67 positive cells with the 
total number of cells (Broyde et al. 2009). Ki-67 expression is correlated with the 
proliferation rate and is therefore used to evaluate the proliferative activity of lymphomas 
(Miller et al. 1994; He et al. 2014). The prognostic effect of Ki-67 was noticed in 
retrospective studies when the proportion of Ki-67 positive cells was correlated with 
grade and outcome in NHL cases (Miller et al. 1994; Broyde et al. 2009; Yoon et al. 
2010; Li et al. 2012). However, there is no consensus on the cut-off value for Ki-67 
expression that can predict outcome. Generally, a value above 70% seems to have 
prognostic value. Broyde et al. (2009) determined that a cut off value of 70% was 
prognostic in DLBCL. Low expressing DLBCL patients had good prognosis compared to 
the high expressing patients  treated with both CHOP and R-CHOP (Broyde et al. 2009).  
Similar results were also observed when Ki-67 was combined with other prognostic 
factors such as  low IPI and bulky disease (Broyde et al. 2009). A study by Yoon et al 
(2010) used a prognostic cut off value of 85% in patients treated with R-CHOP and 
CHOP. Patients with higher Ki-67 expression levels had higher rates of relapse after 
treatment with R-CHOP (Yoon et al. 2010). In addition, the high expression group  had 
significantly lower 2 year event free survival (EFS) and overall survival (OS) rates (Yoon 
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et al. 2010). In another Chinese study, a lower cut off value of 75% can distinguish 
patients with a good or bad prognosis (Li et al. 2012). As with the previous study, high 
expression of Ki-67 was correlated with poor OS and PFS in DLBCL patients treated 
with R-CHOP (Li et al. 2012).  Therefore, although there is no consensus on the cut-off 
values for Ki-67, expression levels above 70% seem to be prognostic. In addition, high 




1.7.3.2 BCL- 2 
 
B-cell leukemia/lymphoma-2 gene (BCL-2) forms part of a family of apoptotic 
regulatory proteins. BCL-2 functions as an anti-apoptotic factor that is important in 
normal B cell development and is frequently overexpressed in DLBCL (Dunleavy & 
Wilson 2011; Iqbal et al. 2004). One well-characterized mechanism of BCL-2 over-
expression is the t(14; 18)(q32; q31) translocation with the Ig gene. This rearrangement is 
largely restricted to the GCB subtype (Iqbal et al. 2004), whereas in the ABC subtype, the 
mechanism of BCL2 overexpression is associated with constitutive NF-kB activation, 
with or without 18q21 amplification (Iqbal et al. 2006). While the BCL-2 gene 
rearrangement has no prognostic significance (Iqbal et al. 2004; Kramer et al. 1998), the 
prognostic significance of BCL-2 protein expression is controversial and subtype 
dependent. In the CHOP era, BCL-2 protein expression was indicator of poor outcome 
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indicator, especially in the ABC subtype (Sohn et al. 2003; Iqbal et al. 2004; Dunleavy & 
Wilson 2012). However, in the post rituximab era, BCL-2 is prognostic in the GCB 
subtype (Perry et al. 2014), raising questions about the differential activity of rituximab 
within the GCB and ABC subtypes of DLBCL (Dunleavy & Wilson 2012).  
1.7.3.3 BCL 6 Gene Rearrangements 
BCL6 is a zinc finger transcription factor that functions as a proto-oncogene, specifically 
acting as a transcriptional repressor needed for germinal centre formation (Westin & 
Fayad 2009). The BCL6 gene is found to be frequently translocated and hypermutated in 
DLBCL. Rearrangement of the BCL6 proto-oncogene at chromosome 3q27 is the most 
frequent cytogenetic abnormality in DLBCL, occurring in up to 35% of cases (Shustik et 
al. 2010; Akyurek et al. 2012). BCL6 rearrangement is associated with elevated lactate 
dehydrogenase (LDH) and advanced age (Jerkeman et al. 2002). No association between 
BCL6 rearrangement status and expression of BCL2, Ki-67 or TP53 was found. The 
evidence for the prognostic significance of BCL6 rearrangement in DLBCL is 
contradictory.  Some studies report no significance (Jerkeman et al. 2002), Kramer et al 
1998) while others do (Akyurek et al. 2012). Differences in the rearrangement detection 
method, cut-off value as well as the classification of DLBCL may account for the 
differences. What is consistent is that BCL6 rearrangement is associated with the non-GC 
phenotype, therefore pointing to the involvement of BCL6 in the process of B cell 
differentiation (Akyurek et al. 2012; Shustik et al. 2010). In addition, the detection of 
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BCL6 protein using IHC does not confer any prognostic significance (Akyurek et al. 
2012; Shustik et al. 2010).  
 
 
1.7.3.4 P53 Genetic mutations and protein expression 
 
The P53 gene is a tumour suppressor gene located on chromosome 17 and encodes a 
53kDa protein (Harris 1996).  P53 is known to play a critical role in cellular responses 
since it responds to damaged DNA by induction of G1 arrest, and if DNA is not repaired, 
p53 may induce apoptosis (Carbone & Gloghini 2014). The dysfunction and mutation of 
p53 can result in abnormal cell growth, lack of apoptosis and eventually malignant 
transformation (Zainuddin et al. 2009). P53 mutations (point mutations and deletions) 
were observed to predict inferior survival in low risk DLBCL cases as well as GC 
phenotype cases (Leroy et al. 2002; Zainuddin et al. 2009) in the CHOP era. However, 
the addition of rituximab, resulted in p53 mutations additionally having a prognostic 
significance for the non-GC phenotype (Stefancikova et al. 2011; Xu-monette et al. 
2012).  The p53 protein expression was also determined to be prognostically significant 
with strong expression (>30% staining) having an adverse effect on overall survival 
(Leroy et al. 2002; Xie et al. 2014). There are limited studies investigating the association 
between a singular mutation/deletion with survival of DLBCL patients.  A recent study 
attempted to fill this gap by determining the effect of the P53 rs1625895 polymorphism 
in DLBCL patients treated with R-CHOP (Voropaeva et al. 2015). The study observed an 
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increased relapse rate and lower overall survival in patients having the G/G phenotype 
compared to the G/A or the A/A phenotype of the polymorphism (Voropaeva et al. 2015).  
A study by Young et al (2008) showed that mutations in different domains of the protein 
have an impact on prognosis. Patients with mutations in the DNA- binding domain had 
the poorest overall survival rate, while mutations in the loop-L2 region showed no  effect 





Forkhead box protein P1 (FOXP1) is a member of the FOX family of transcription 
factors characterized by a common DNA-binding, winged-helix domain with N-terminal 
zinc finger and leucine zipper domains (Sagaert et al. 2006; Jack & Barrans 2004; 
Barrans et al. 2004). GEP studies have reported upregulated mRNA expression of the 
FOXP1 forkhead transcription factor in response to  B-cell activation(Banham et al. 
2005).  In addition, FOXP1 mRNA is upregulated in the non-GC subtype of DLBCL 
(Barrans et al. 2004; Hoeller et al. 2010). FOXP1 protein is therefore overexpressed in a 
subset of DLBCL cases and is reported to have prognostic significance. FOXP1 protein 
overexpression is associated with lower disease-specific and overall survival in nodal and 
non-GCB DLBCL cases (Barrans et al. 2004; Banham et al. 2005; Hoeller et al. 2010). 
The prognostic significance of FOXP1 expression was independent of the IPI (Barrans et 
al. 2004; Banham et al. 2005; Tzankov et al. 2015).  However, a recent study has reported 
that the extranodal DLBCL group expressing FOXP1 protein also has worse outcome(Yu 
et al. 2011). The discrepancies in the data may be due to differences in the IHC antibody 
used (which may detect related FOX proteins), IHC conditions, as well as the cut-off 





1.7.3.6 MYC Gene Rearrangement 
 
The MYC proto-oncogene family comprises three genes encoding for the transcription 
factors MYC, NMYC, and MYCL that regulate multiple functions in normal cells and 
have a strong oncogenic potential (Karube & Campo 2015). MYC gene rearrangement is 
characteristics of BL and occurs in 10% of DLBCL cases and these alterations are 
frequently associated with BCL-2 or BCL-6 rearrangements (Lin et al. 2012; Karube & 
Campo 2015).MYC gene alterations have prognostic significance in lymphoma cases 
intermediate between BL and DLBCL (Lin et al. 2012). MYC rearrangements were 
observed to be frequently found in extranodal cases of DLBCL and these cases had a 
higher DFS rate (Kramer et al. 1998). While in another study MYC rearrangements were 
associated with lower overall survival, and this was apparent in the GCB subtype 
(Akyurek et al. 2012; Perry et al. 2014).  
Lymphomas with BCL-2 and MYC genetic rearrangements are referred to as “Double 
Hit” lymphomas (Aukema et al. 2011).These genetic aberrations lead to an 
overexpression of the protein which can have prognostic significance (Johnson et al. 
2012). In DLBCL, the overexpression of both MYC and BCL-2 protein has been shown 
to signify poor prognosis (Johnson et al. 2012). The prognostic significance of MYC and 
BCL-2 co-expression is similar in DLBCL subtypes, although the aberrations are 




1.7.4 Biomarkers for HIV-related DLBCL 
 
Prognosis in HIV related DLBCL is determined by factors relating to the tumour as well 
the underlying immunodeficiency (Kaplan 2012). Previously in the pre-HAART era, the 
state of immunodeficiency played a major role in determining prognosis for HIV related 
NHL cases (Lim et al. 2005). However, in the post-HAART era features relating to the 
tumour, such as the IPI, have surfaced as prognostic indicators (Bower et al. 2006; 
Kaplan 2012; Tedeschi et al. 2012). There are limited studies investigating the impact of 
molecular indicators on survival, specifically in HIV-related DLBCL. Preliminary data 
indicate that markers including MYC, BCL-6 and MUM1 are overexpressed in HIV 
related DLBCL (Chao et al. 2015). In addition, markers that may be significant predictors 
of survival in HIV related DLBCL are EBV and MYC expression in patients with low 
CD4 counts (Silverberg et al. 2012). EBV positivity is known to be associated with the 
NF-kB pathway as well as increased mortality in patients with HIV related DLBCL 
(Chao et al. 2013). Chadburn et al (2009) concluded that the known markers for 
prognosis in non HIV related DLBCL do not predict any prognostic significance in HIV 
related DLBCL. However this study combined patients receiving four different types of 
treatment in their analyses (Chadburn et al. 2009). Therefore, more studies are required in 
determining biomarkers for HIV positive DLBCL so as to better understand the 




1.7.5 Biomarkers for DLBCL identified by proteomic methods 
 
There are a number of proteomic studies performed to determine biomarkers for DLBCL. 
Differences between early relapse patients and progression free DLBCL patients have 
been quantified using a SILAC based method in pre-treatment frozen tissues (Rüetschi et 
al. 2015). The authors found an enrichment of proteins involved in the regulation and 
organization of the actin cytoskeleton that could discriminate the two patient groups 
(Rüetschi et al. 2015).  Another study that attempted to elucidate how the tumour 
responds to treatment was conducted using 2D coupled to mass spectrometry. The 
authors identified 19 differentially expressed proteins between chemoresistance and 
chemosensitive causing chemotherapy resistance.  The study highlighted proteins 
involved in cell proliferation and apoptosis such as the FGF signaling pathway as well as 
the Ca2+- calmodulin-related signaling pathways as the main driving force behind 
chemoresistance (Liu et al. 2013). An additional SILAC based study attempted to 
segregate the GCB and ABC subtypes of DLBCL. The main proteins that were 
differentially expressed between the subtypes included cell surface markers CD44 and 
CD27, transcription factors IRF4 and SPI1 (Deeb et al. 2012). Several studies have used 
serum to identify biomarkers which have high accuracy and specificity (Zhang et al. 
2007). However, the identities of these potential biomarkers are unknown because the 
classification models can be used as is without identifying the peaks. Researchers need to 
take a further step and identify the proteins that make up the classification models. 
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Knowing the identity may assist in better understanding the disease processes and thereby 
assist in developing alternate therapeutic options.  
There is currently no literature on potential biomarkers for HIV related DLBCL 
discovered using proteomic methods. 
1.7.6 Disadvantages of proteomic biomarkers 
 
The search for new biomarkers for cancer is a great step towards finding alternative 
therapeutic agents that can be used to effectively treat all variants of DLBCL. However, 
before any of the biomarkers identified can be ready for clinical trials a number of 
challenges need to be overcome. One of the major challenge is to conquer errors of study 
design  and/or experimental execution (Drucker & Krapfenbauer 2013). Studies need to 
have well-characterized and adequately stored clinical samples collected using 
recommended procedures together with detailed information on clinical, pathological 
parameters and follow-up (Matta et al. 2010). Another challenge is limited sample 
number. The majority of biomarker studies use limited clinical samples as large numbers 
of samples is beyond the scope of a single centre (Mayeux 2004). In addition, due to the 
heterogeneity of cancers, single biomarkers may not offer enough sensitivity and 
specificity (García-Bilbao et al. 2012). Therefore, the solution would be to validate a 






1.8 AIMS AND OBJECTIVES 
As mentioned in section 1.7.3 there has been considerable focus on determining 
biomarkers for DLBCL in the HIV negative context as this will aid in advancing 
knowledge on the development and progression of this disease. In contrast, there are 
limited studies on molecular markers for DLBCL in the HIV positive context, thus 




 The aim of the project is to identify biomarkers for HIV and non- HIV related 




 Determine the clinicopathological differences between HIV and non-HIV 
related DLBCL. 
 Identifying protein biomarkers present in both the HIV and non-HIV related 
DLBCL using MALDI Imaging MS. 
 Characterize the identified proteins using LC-MS/MS. 
 Correlate the resulting molecular data with clinicopathological information. 
 Determine the expression levels of microRNA-21 in HIV and non-HV related 
DLBCL (This part of the project was completed and published as seen in 
Appendix P). 
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CHAPTER 2:  THE CLINICOPATHOLOGICAL FEATURES OF 
DLBCL IN HIV NEGATIVE AND POSITIVE PATIENTS 
2.1 INTRODUCTION 
Diffuse large B cell lymphoma makes up 30% of all NHL cases in developed countries 
with an even higher frequency in developing countries (Zhou et al. 2013; Mey et al. 
2012). DLBCL can occur at all ages but has a median age at diagnosis of 64 years (Hunt 
& Reichard 2008). The disease is aggressive in nature and occurs at nodal or extranodal 
(EN) sites (Hunt & Reichard 2008). Up to 40% of DLBCL cases are extranodal with the 
gastrointestinal tract being the most common site (López-Guillermo et al. 2005; Vishnu 
& Aboulafia 2012). In 1993, the International prognostic index (IPI) was established as a 
prognostic predictor for NHL and is now the gold standard for determining prognosis 
(Sehn et al. 2007; Shipp & The international non-Hodgkins lymphoma prognostic factors 
1993). Treatment involves the administration of six to eight cycles of CHOP 
(cyclophosphamide, doxorubicin, vincristine, prednisone) (Mey et al. 2012) with 
complete response (CR) rate between 48-60% (López-Guillermo et al. 2005; Montes-
Moreno et al. 2010).  The addition of the CD20 antibody, rituximab (R), has improved 
the complete response rate by 10% (Salles et al. 2011) .  
HIV associated DLBCL is also the most common HIV associated lymphoma, with a 
frequency of up to 50% (Wang & Castillo 2011; Patel et al. 2015). Prior to the HAART
era, HIV positive patients had a 60-200 times increased risk of developing NHL 
compared to the HIV negative population (Beral et al. 1991). However, since the 
introduction of HAART the risk of acquiring NHL has decreased due to increased CD4 
counts and decreased viral load (Grogg et al. 2007). The introduction of HAART has also 
improved the outcome of HIV positive patients with DLBCL (Patel et al. 2015; de Witt et 
al. 2014). 
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The morphology of HIV-DLBCL tumours are similar to that seen in HIV uninfected 
counterparts (Gloghini et al. 2013b). However, there may be significant 
clinicopathological differences observed between the two groups (Barreto et al. 2012).  
The aim of the study was to determine the differences in the clinicopathological features 
of HIV positive and negative patients diagnosed with DLBCL at a single centre tertiary 
hospital.  
2.2 MATERIALS AND METHODS 
2.2.1 Ethics approval 
The study was approved by the University of Cape Town Human Research Ethics 
Committee (reference HREC REF: 261/2010). The research proposal was approved by 
the Department of Clinical Laboratory Sciences Research Committee and the Faculty of 
Health Sciences Postgraduate Committee at the University of Cape Town.   
2.2.2 Case selection 
The study was a retrospective analysis of all DLBCL patients diagnosed and treated at 
Groote Schuur Hospital over 11 years (1st January 2003 until 31th December 2013).An 
electronic search was performed for cases diagnosed as “malignant lymphoma large cell 
diffuse, NOS” and “diffuse large cell lymphoma” from the laboratory information system 
database of the Division of Anatomical Pathology, National Health Laboratory Service, 
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using the Systemized Nomenclature of Medicine (SNOMED) code: M-96803. The 
generated list was used to search for patient folders at the Department of Radiation 
Oncology, GSH. The SNOMED codes, M-95953, M-95913, M-95903 were also used to 
search for additional cases.  
 
2.2.3 Folder selection 
The information from the list generated from the large cell lymphoma SNOMED 
mentioned in section 2.2.2 was used to look for the Department of Radiation Oncology 
folder number (RT number) which was different from the main hospital folder number.  
Baseline demographic and clinicopathological data were extracted, including treatment, 
response and survival. The following cases were excluded: 
 Cases with no RT number 
 Cases with missing folders 
 Cases not diagnosed as Diffuse Large B cell lymphoma 
 Cases with no HIV test result 
 Patients with lymphoma intermediate between BL and DLBCL 
 
The following DLBCL subtypes were included: 
 Sclerosing DLBCL (4 cases) 
 T-cell/histiocyte rich large B cell lymphoma (10 cases) 




2.2.4 Treatment of DLBCL patients 
The majority of DLBCL patients were treated with CHOP therapy without rituximab. 
Twelve of the HIV negative patients from 2012-2013 were treated with R-CHOP. 
Intrathecal chemotherapy was used in patients with central nervous system (CNS) 
disease. Some patients in this study also received dose-reduced chemotherapy, palliative 
radiotherapy and involved field radiotherapy. HIV negative patients who had poor 
response to CHOP or relapsed were considered for high-dose salvage chemotherapy and 
stem cell transplantation. HIV positive patients who responded poorly to CHOP received 
palliative radiotherapy and/or chemotherapy. All HIV positive patients received HAART 
either prior or after diagnosis (Pather et al. 2013). 
 
2.2.5 Classification into nodal and extranodal 
We decided to classify nodal and extranodal tumours using criteria stated in Moller et al 
(2004). Lymphomas with clinically dominant lymph node involvement, as well as those 
presenting at the spleen or Waldeyer’s ring, were considered as nodal lymphoma. Patients 
were defined as having extranodal DLBCL when the disease after the staging procedures 
was confined to one or more extranodal sites and with no (or only minor) nodal 
involvement. Primary tumour site was categorized into gastrointestinal (GI) tract, breast, 
hematologic system (blood, and bone marrow), genitourinary tract, head and neck, 
liver/pancreas, respiratory system, skeletal tissue, skin/soft tissue and thyroid. 
 
2.2.6 Statistical analysis 
The statistical analysis of the data was performed using Stata 12 unless otherwise stated. 
Comparisons between numerical variables were conducted with an unpaired t test. 
Categorical variables were compared using chi-square or Fischer’s exact test, depending 
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on frequency levels. The linear regression analyses were completed using STATISTICA 
12 with default settings. Categorical variables were coded and correlated with patient 
outcome (Appendix A).  Overall survival was calculated from the date of first treatment 
to the date of death or last contact. Kaplan- Meier survival curves were drawn for overall 







2.3.1 Baseline characteristics of HIV negative and HIV positive DLBCL 
 
There were 556 cases diagnosed as DLBCL from 2003-2013 using the NHLS database, 
however only 263 folders were located (Table 2.1). Patient age at diagnosis ranged from 
13 years to 92 years, with a median of 52 years (Table 2.1). The majority of the located 
cases were HIV negative (205/263) but a few of the cases had no record of HIV status 
(4/263) (Table 2.1). The HIV positive cases had a statistically significant lower age at 
diagnosis with a median of 40 years, compared to 55 years of the HIV negative cases (p< 
0.0001) (Table 2.1). There were only 219 cases with recorded gender, with females being 
the predominant gender (117 females vs. 102 males). This was observed in both HIV 
negative and HIV positive groups (Table 2.1). There were 192 and 200 cases with B 
symptoms and bone marrow involvement recorded, respectively. Equal numbers of the 
HIV negative and HIV positive DLBCL cases presented with B symptoms (35% vs. 
34.7%) and bone marrow involvement (BMi) (42% vs. 46%). 
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Table 2.1: The clinical biological parameters of DLBCL from HIV infected and HIV uninfected patients 
 ALL DLBCL HIV- DLBCL HIV+ DLBCL P Values 
N % N % N % 
Number of patients 2631 100 205 77.9 54 20.5  
Median age (range) 52 (13-92) 55 (13-92) 40(14-72) <0.0001 
Male Gender 
N (Total) 
102 (219)2 46.6 79(166) 47.6 23 (53) 43.2 0.594 
Ann Arbor Stage (Total) 244 195 49 0.057 
I 45 18.44 36 18.46 9 18.37 
II 66 27.05 59 30.26 7 14.28 
III 33 13.52 22 11.28 11 22.45 
IV 100 40.92 78 40 22 44.90 
IPI Score (Total) 84 82 2 0.121 
0 9 10.71 9 10.98    
1 19 22.62 19 23.2    
                                                 
14 cases had no recorded HIV status  
2 44 cases did not have recorded gender 
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2 14 16.67 14 17.1    
3 20 23.81 20 24.4    
4 16 19.04 14 17.07 2 100  
5 6 7.14 6 7.32    
Elevated LDH (> 480 U/L) 56 (81) 69.14 42 (66) 63.64 14 (15) 93.33 0.025 
ECOG Performance Status 238 187 51 0.980 
0 18 7.56 14 7.49 4 7.84 
1 107 44.96 85 45.45 22 43.14 
2 40 16.81 30 16.04 10 19.61 
3 48 20.17 38 20.32 10 19.61 
4 25 10.50 20 10.7 5 9.8 
B symptoms 67 (192) 34.9 50 (143) 35 17 (49) 34.7 0.973 
Bone Marrow Involvement 57 (200) 28.36 42 (154) 27.27 15 (46) 32.61 0.482 
Tumour site  0.353 
Nodal 127 (249) 51.00 101 (198) 51.01 26 (51) 50.98 





There were 244 and 238 cases with Ann Arbor stage and performance status (PS) 
recorded, respectively (Table 2.1). The majority of the HIV negative cases were 
classified as stage II and stage IV (30.26% and 40%) (Table 2.1). In contrast, the majority 
of cases in the HIV positive group were classified as stage III and stage IV (44.90% and 
22.45%). The predominant cases (44.96%) with recorded data had a performance status 
of 1. This was observed for both HIV negative (45.45%) and HIV positive (43.1%).  
There were 84 cases with IPI recorded, of which 82 were HIV negative. Only 2 of the 
HIV positive cases had IPI status calculated and recorded.  
 
Just 51% of all DLBCL tumours were nodal lymphomas (Table 2.1). Similar percentages 
for nodal cases were observed for both HIV negative and HIV positive DLBCL cases 
(Table 2.1). In addition, no differences in median OS between nodal and extranodal 
lymphoma cases were observed for both HIV negative (9.1 years vs. 6.3 years) and HIV 
positive cases (5.0 years vs. 2.7 years) (Appendix B). The most common extranodal sites 
were the GI tract (40/122), bone (23/122) and the respiratory system (15/122) (Figure 
2.1). There were no differences in OS between the three most common exrtanodal sites in 
the HIV negative group (Figure 2.4). The 10 year OS rates were 65.45% for GI tract, 
50.22% for respiratory system and 23.98% for skeletal site  
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Figure 2.1: The frequency of the various DLBCL extranodal sites. The GI tract and 
skeletal sites were the most frequently observed. 
2.3.2 Statistical analysis of Oncology data 
Differences between the clinicopathological parameters of HIV negative and HIV 
positive DLBCL were compared using chi square and t-test. No statistically significant 
differences in gender, Ann Arbor stage, performance status, B symptoms, primary 
tumour site and bone marrow involvement were observed (Table 2.1).  The only 
statistically significant differences observed were in median age and elevated LDH 












levels (higher than 480 U/L) compared to the HIV negative group (93% vs. 63%, p < 
0.05).  














Figure 2.2: Kaplan Meier survival curve of DLBCL cases treated at GSH 
2.3.3Treatment outcome of DLBCL patients 
The median survival of all DLBCL patients was 8.6 years (Figure 2.2) with the patients 
receiving CHOP treatment having a median of 2.24 yrs vs. 8.34 yrs for HIV positive and 
HIV negative patients, respectively (Figure 2.3). The five year OS was 56% vs. 46% for 
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HIV negative vs. HIV positive DLBCL patients (p = 0.048) (Figure 2.3).  The HIV 
negative patients had higher complete response (CR) rates compared to HIV positive 
patients (47% vs. 40%) (Table 2.2). The relapse rate in the HIV negative group was 
higher than the rate of the HIV positive group (10% vs. 8%) (Table 2.2).  
 
Table 2.2: Complete response and relapse rates of the DLBCL patients treated at GSH. 
DLBCL  CR Relapse (after CR) No CR Total 
HIV neg N 95 20 86 201 
% 47.26 9.95 42.79 100 
HIV pos N 21 4 27 52 
% 40.38 7.7 51.92 100 
 Total 116 24 113 253 
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Figure 2.3: Kaplan Meier survival curve of HIV infected (HIV +) and HIV uninfected 




Table 2.3: The surviving proportions of DLBCL patients at 3, 5 and 10 year intervals. 
Years elapsed HIV-DLBCL HIV+DLBCL HIV- DLBCL ( R ) 
3 58.40% 46.30% 90.91% 
5 56.60% 46.30% 90.91% 
10 50.70% 23.10% 90.91% 




2.3.4 Prognostic factors affecting overall survival 
Linear regression was performed to determine the clinicopathological prognostic 
indicators affecting patient outcome. The clinicopathological parameters were given 
codes for the analysis (Appendix A). The analysis was performed on all the DLBCL 
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patients irrespective of HIV status prior to analysing the two cohorts of the study.  
Advanced age and stage were associated with poor prognosis for all DLBCL patients 
(Table 2.4). In addition, bone marrow involvement and female patients were associated 
with poor prognosis for all DLBCL patients (Table 2.4). The same factors were 
significant in HIV negative patients with the inclusion of primary extranodal tumour site, 
which was a poor prognostic indicator (Table 2.4).  



















G I tra c t
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Figure 2.4: Kaplan Meier graph comparing the OS of extranodal lymphoma patients 
presenting in GI tract, respiratory and skeletal sites in the HIV negative cohort. 
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Table 2.4: The linear regression analysis of prognostic factors affecting overall survival. The 
HIV infected cohort did not have significant prognostic indicators. 
Factor ALL DLBCL patients HIV – DLBCL patients HIV + DLBCL patients 
 B S.E of 
B 








Age 0.15 0.0615 0.02 0.17 0.0691 0.0014 0.11 0.14 0.44 
Gender -0.15 0.0667 0.03 -0.20 0.0765 0.0098 0.01 0.14 0.95 
Stage 0.17 0.0632 p<0.001 0.16 0.0711 0.03 0.2 0.14 0.18 
BMi -0.24 0.0690 p<0.001 -0.23 0.0789 0.004 -0.26 0.14 0.07 
EN 
lymphoma 
0.08 0.06 0.23 -0.14 0.0707 0.04 0.13 0.14 0.36 
IPI -0.07 0.06 0.49 -0.07 0.11 0.54 N.D N.D N.D 




0.02 0.07 0.79 0.01 0.1 0.94 -0.02 0.14 0.86 
HIV status 0.04 0.06 0.49 N.D N.D N.D N.D N.D N.D 
CD4 count -0.09 0.14 0.53 N.D N.D N.D 0.06 0.14 0.70 








The study determined the clinicopathological differences between HIV negative and HIV 
positive DLBCL cases. The DLBCL cases diagnosed and treated at GSH were located by 
using a NHLS list. The number of patients treated at GSH was lower than expected due 
to a number of reasons. The cases diagnosed by the NHLS Anatomical Pathology 
laboratory at Groote Schuur hospital are not all treated at the GSH Department of 
Radiation Oncology. In addition, the SNOMED code used to create the list is not specific 
for DLBCL and includes large T cell lymphomas. The SNOMED system used is not 
aligned to the current WHO classification of lymphomas. We observed a median age for 
DLBCL cases occurring at the early sixth decade (Table 2.1), thus confirming previous 
studies (Bürgesser et al. 2013; Flowers et al. 2013; Hunt & Reichard 2008; Castillo et al. 
2014). The lower median age at diagnosis for HIV positive DLBCL patients has been 
previously reported and ranged in the fourth decade in South Africa (Wiggill et al. 2011; 
de Witt et al. 2014) and fifth decade abroad (M. J. Baptista et al. 2015). 
Our study observed a female predominance, in both HIV negative and positive groups 
which is contrary to the male predominance previously reported (Sarkozy et al. 2014). 
This may be due to the 44 cases with no recorded gender which could have skewed the 
data towards a female predominance. However, possible reasons for  gender differences 
in cancer have been elucidated for other cancers, yet this has not been done for 
lymphoma (Mester et al. 2006). In addition, the increased number of females in the HIV 
positive group may be due to relatively larger numbers of females that are infected with 
HIV in South Africa (UNAIDS 2015; Shisana et al. 2012). This is in keeping with a 
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similar study conducted previously in South Africa showing an overrepresentation of 
females (Wiggill et al. 2011). 
 
We did not observe any statistical difference in IPI, stage, PS and frequency of B 
symptoms between the HIV negative and positive DLBCL groups (Table 2.1). This is in 
contrast with a study done in a Spanish population (M. J. Baptista et al. 2015) which 
showed that HIV infected patients were more likely to have worse prognostic indicators 
(higher PS scores, frequent B symptoms and a higher stage). The differences observed 
may be due to poor socio-economic status impacting on patient survival (Tao et al. 2014). 
Our study observed that the HIV positive group frequently had higher LDH levels which 
confirm other studies reporting the difference in LDH levels (Table 2.1) (J. M. Baptista et 
al. 2015; Williams & Churchill 2007; Lu et al. 2013). The LDH enzyme catalyses the 
conversion of pyruvate to lactate and is considered to be a key enzyme of glycolysis. It is 
elevated in many types of cancers and has been linked to tumour growth, maintenance, 
and invasion (Miao et al. 2013). A disturbed cellular metabolism due to cancer and 
infectious conditions may trigger release of high levels of LDH into the blood stream 
(Ramana et al. 2013). In addition, HAART has also been shown to result in elevated 
LDH in HIV positive individuals due to their role in the inflammatory response (Blanco 
et al.). Therefore this parameter may be frequently elevated in the HIV positive group due 
to HIV infection as well as HAART intake.  
 
The HIV positive DLBCL group had significantly lower overall survival, thus affirming 
published data (Figure 2.3) (J. M. Baptista et al. 2015; de Witt et al. 2014). However, the 
3 year OS rate for HIV positive DLBCL in our study was higher than the one published 
by de Witt (2013) despite study population emanating from the same region. The reason 
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for the differences observed may be the varying treatment regimens received in our 
patients, whereas his cohort received CHOP only. The CR rates were higher in the HIV 
negative cohort confirming previously published data (J. M. Baptista et al. 2015). 
Although a higher relapse rate in the HIV positive group was expected, it was 
interestingly higher in the HIV negative group (Table 2.2). This could have resulted from 
a higher death rate in the HIV positive group, leading to a low percentage of the 
surviving population which may have low relapse rate (Figure 2.3, Table 2.3).  
 
We did not observe any statistically significant differences in the distribution of nodal 
and extranodal cases between the two DLBCL groups (Table 2.1). This is different from 
the study by Pather et al (2013) who found HIV positive cases to be more likely to have 
extranodal tumours. The contradiction may be due to differences in sample size as well as 
the inclusion of plasmablastic lymphoma cases in their analysis. In addition, differences 
in the classification systems used to classify nodal and extranodal lymphomas may also 
result in contradictions. For example, some studies include the Waldeyer’s ring in nodal, 
while others exclude this  (Castillo et al. 2014; López-Guillermo et al. 2005). This may 
lead to discrepancies in the frequency of nodal and extranodal cases. Our study confirms 
previous data suggesting that the GI tract is the most common extranodal site (López-
Guillermo et al. 2005). In addition our study indicated that extranodal tumour site was 
associated with worse outcome in the HIV negative group,  and this was also seen in 
previous studies (Castillo et al. 2014).  Our results indicated that skeletal/bone extranodal 
sites have a lower median survival in the HIV negative group although this was not 
significant (Figure 2.4). We could not however, determine the effect that each extranodal 
site has on outcome due to low sample size on most groups, especially in the HIV 
positive group. However, previous studies indicate that the GI tract and liver/pancreas 
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demonstrated the worst outcome (Castillo et al. 2014). A larger cohort made up of 
multiple centres may assist in determining the prognostic effect of each extranodal site in 
the Southern African population. The prognostic effect of extranodal tumours may lie in 
the genetic and molecular differences inherent between nodal and extranodal tumours 
(Al-humood et al. 2011; López-Guillermo et al. 2005). Extranodal lymphomas have 
frequent gains of chromosomal arms 1p, 7p, 12q24.21-12q24.31 and loss of chromosome 
4, 6q, and 18q22.3-23 while nodal lymphomas frequent 18q amplification and BCL2 
protein overexpression (Al-humood et al. 2011). 
Our finding regarding age, stage, bone and marrow involvement indicated that they were 
prognostic indicators for all DLBCL patients, including the HIV negative cases (Table 
2.2). The study by Klapper et al (2012) showed that increased age was associated with 
poor prognosis. In addition, age, stage and extranodal sites are part of the International 
Prognostic Index (Shipp et al. 1993) highlighting their importance as prognostic markers. 
Bone marrow involvement has been previously identified to negatively affect overall 
survival (Shim et al. 2013). Our study reports that the female gender is associated with 
worse prognosis. This result is contrary to the studies performed in other parts of the 
world which indicate that males have worse prognosis (Yıldırım et al. 2015; Sarkozy et 
al. 2014).  The poor prognosis in females in our cohort may be due to the increased risk 
of anthracycline therapy induced cardiotoxic side effects in females (Volkova & Russell 
2011). 
The study was limited by the lack of proper record keeping in the patient folders. This 
resulted in inability to determine the differences in IPI score distribution between the two 
groups. The lack of alternative treatment options for DLBCL and workload of 
oncologists may affect the ability to accurately record prognostic factors for each patient. 
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In addition, the study population was not uniform since mediastinal DLBCL and T cell 
rich large B cell lymphoma subtypes were included. These are considered as distinct 
entities by WHO and may affect the results (Jaffe 2009). The patients were also not given 
uniform treatment as mentioned in section 2.2.4 which may mask the effect of CHOP 
therapy on DLBCL subtypes. Moreover, some of the recent cases (2012-2013) belonging 
to the HIV negative group were given R-CHOP and may have had a better prognosis 
compared to their HIV positive counterparts (Rovira et al. 2015; Cultrera & Dalia 2012). 
Interestingly, R-CHOP has been reported to not offer survival improvement in Southern 
Africa, so it is possible that the addition of rituximab did not influence patient survival 
(Sissolak et al. 2013). Finally, given adequate financial resources, the study would have 
benefitted from comparisons of patients who belonged to the same molecular subtype as 
well as given similar treatment type.  
 
In summary, our study observed that HIV negative and HIV positive DLBCL patients 
have similar clinicopathological features but, they differ in median age at diagnosis and 
frequency of elevated LDH levels. The HIV positive DLBCL group was also shown to 
have poorer overall survival. Finally, age, gender, stage and bone marrow involvement 
were calculated to be prognostic indicators for all DLBCL patients irrespective of HIV 
status. In addition, the presence of lymphoma in extranodal sites was also prognostic for 




CHAPTER 3: BIOMARKER IDENTIFICATION USING MALDI 




MALDI IMS is a powerful technology which investigates the content and distribution of 
molecules in tissues while preserving their morphological structure (Balluff et al. 2011). 
Therefore, it has great potential in the field of biomarker discovery as proteins, lipids and 
metabolites can be analysed without prior knowledge of their presence or the need for 
labelling (Caprioli et al. 1997; Balluff et al. 2011). MALDI IMS has various applications 
including: molecular classification of tissue, analysis of intra-tumour diversity and the 
determination of drug metabolism kinetics (Castellino et al. 2011; Schöne et al. 2013). 
Molecular classification of tissues can lead to the identification of markers used for 
patient diagnosis (Rauser et al. 2010), prognosis (Balluff et al. 2015), and response to 
therapy (Reyzer & Caprioli 2005).  
The previous chapters highlighted the need for biomarkers for DLBCL, especially in the 
HIV context. Below, we describe the identification of biomarkers for HIV related and 
non-HIV related DLBCL, using MALDI IMS.   
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3.2 MATERIALS AND METHODS 
3.2.1 Study samples 
The study consisted of 12 FFPE tissue samples including four reactive nodes and eight 
DLBCL samples. There were four DLBCL samples from HIV negative samples and four 
from HIV positive samples. Similarly, two reactive nodes were taken from HIV negative 
and HIV positive samples, respectively. The baseline demographics of the study cohorts 
can be seen in Appendix G. In addition, 52 samples were used to validate the expression 
of Hsp70 using immunohistochemistry (Appendix J). 
3.2.2 Tissue preparation 
FFPE tissue blocks were sectioned on a rotary microtome at 10 µm. Tissue sections were 
picked up poly-L-lysine coated (Appendix E) indium tin oxide (ITO) glass slides and 
baked on a hot-plate at 60 °C for 10 min. The slides were then brought down through 
three xylene washes of 5 min each to enable dewaxing. This was followed by washing in 
three successive 100% ethanol baths to facilitate clearing of tissues. Sections were then 
washed well in distilled water for 5 min and left to air dry at room temperature (RT) prior 
to processing. 
3.2.3 Hematoxylin & Eosin (H&E) Stain 
Tissue sections were cut at 3µm and prepared as mentioned above before incubating in 
Mayers Hematoxylin solution (Appendix F) for 5 min at RT. This was followed by 
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washing and bluing of nuclei with ammoniated water (Appendix F). The cytoplasm of the 
tissues was stained with phloxine eosine solution (Appendix F) for 2 min. The sections 
were then dehydrated with alcohol baths, cleared with xylene baths prior to mounting on 
cover slips.  The H&E stained slides were then viewed by a pathologist and the tumour 
region demarcated. 
3.2.4 Methodology for MALDI IMS 
3.2.4.1 Tissue digestion for MALDI IMS 
The tissue sections were prepared as described in section 3.2.2andwere left to dry at RT. 
The trypsin solution (5 ng/µl in 50% acetonitrile; 50 mM ammonium bicarbonate, pH 8) 
was automatically spotted on the tissue using the trypsin deposition settings on 
ImagePrep (Bruker).  The slide was then incubated at 100% humidity at 37 °C for 15 hr 
to facilitate digestion.   
3.2.4.2 MALDI Imaging mass spectrometry of digested FFPE tissues 
Following on tissue digestion, the α-cyano-4-hydroxycinnamic acid (HCCA) matrix (7 
g/l in 60% acetonitrile, 0.2% trifluoroacetic acid) was deposited onto sections using the 
HCCA settings on Imageprep. External calibration was performed using Bruker peptide 
calibration standard II. The Imaging analysis of the tissue was carried out by rastering at 
100 µm by 100 µm pixel sizes. The spectra were acquired by firing a 337 nm laser (20 
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µm laser spot size) at a rate of 50 shots per raster spot. A mass spectrum was acquired for 
each set of spatial coordinates based on 2500 shots per pixel area accumulated in a 
random walk mode. The spectra were collected in positive reflectron mode in the m/z700 
-3500 range. Image acquisition was carried out using the FlexControl 3.0 software 
package (Bruker). MALDI parameters were set as follows: 25 kV-22.45 kV acceleration 
voltage, 8.00 kV lens voltage, 26.71 kV reflector voltage and 13.35 kV final acceleration, 
with up to 400 Da suppression.  
 
3.2.4.3 IMS data analysis 
3.2.4.3.1 Data exportation 
 
Regions of Interests (ROIs) in the tumour region of tissue sections were drawn on the 
scanned tissue section image on FlexImaging 3.0 software (Bruker). The follicular 
regions in the control tissue sections were chosen as ROI (Appendix C).  For each 
sample, the spectra within the ROIs were exported as xml files. Statistical analyses were 
performed on pooled spectral data from each sample group. Fifty randomly chosen 
spectra from each ROIs were selected using Spectral Importer software (Bruker) and 
comparison groups were created and given a colour.  The spectra within the groups were 
then recalibrated and normalized prior to statistical analyses on Clinprotools 3.0 (Bruker).  
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3.2.4.3.2 Spectral recalibration and normalisation 
Recalibration of the spectra on Clinprotools 3.0 (Bruker) was performed at a resolution of 
a 1000, with a mass range between m/z100 -5000 and a data reduction of two.  The 
background from the spectra was subtracted using the TopHat baseline correction and 
normalised using the total ion count (TIC) method. The selection of statistically relevant 
peaks was done on the total average spectra selecting peaks with a signal to noise ratio of 
at least 20 (Appendix Q).  
3.2.4.3.3 Principal Component Analysis (PCA) and Hierarchical Clustering 
PCA was performed on recalibrated spectra with a ‘level’ scaling method keeping 95% 
variance of the data.  Hierarchical clustering was performed on PCA data with Euclidean 
distances and the ward linkage method used to measure the distances between two points. 
The data was reduced to 95% of the explained variances and the tree drawn with a 
maximum of 5 path lengths. 
3.2.5 Protein extraction for LC-MS/MS 
The same tissue sections that were used for MALDI IMS were washed in 70% ethanol to 
remove the matrix. They were then subjected to in situ trypsin digestion using the settings 
stated in section 3.2.4.1.  The peptides were extracted with, 20 µl of 10% acetonitrile 
(ACN) was pipette up and down the tissue section for 1 min. The extract was then 
concentrated using a speedvac for 1 hr. A 2 µl aliquote was then mixed with 10 µl 0.1% 
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trifluoroacetic acid (TFA) and taken through the zip tip method (Appendix E). This was 
then subjected to nLC-MS/MS analysis.  
3.2.6 Protein Identification 
3.2.6.1 nLC-MS separation of peptide extract 
The peptide extract was first separated usingliquidchromatographyon a Thermo Scientific 
EASY-nLC II connected to a Proteineer fc II protein spotter controlled through HyStar 
software.  The separation was performed on an EASY column (2cm, 75µm ID, 5µm, 
C18) pre-column followed by an analytical column (10cm, 75µm ID, 3µm, C18) with a 
flow rate of 100µl/hr using a 48 minute gradient run (Table 3.1). The eluent were spotted 
on a MALDI plate (MTP 384 target plate) with a saturated HCCA matrix every 15s. The 
plate was further processed with MALDI-TOF MS. 
3.2.6.2 MALDI-TOF of spotted peptides 
MALDI-TOF MS and LIFT MS/MS was performed using an UltrafleXtreme MALDI 
ToF/ToF system (Bruker Daltonics, Bremen, Germany) with instrument control through 
Flex control 3.4. Peptides were ionized with a 337 nm laser and spectra acquired in 
reflector positive mode at 28kV using 100 laser shots per spectrum with a scan range of 
m/z =700 -4000. Spectra were internally calibrated using peptide calibration standard 
II(Bruker). Peptide spectra of accumulated 4,000 shots were automatically processed 
using WARP LC 3.2 software (Bruker) 
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Table 3.1: The gradient run for the nLC-MS analysis 
Time (min) Function Value 
0 Flow rate 300nl/min 
0 Solvent Mix 98% A , 2% B        
44 Solvent Mix 65% A , 35% B 
48 Solvent Mix 60% A , 40% B 
48.10 Solvent Mix 0% A , 100% B 
60 Solvent Mix 0% A , 100% B 
60.10 Solvent Mix 98% A , 2% B 
70 Solvent Mix 98% A , 2% B 
A: 0.05%TFA/H2O, B: 0.05%TFA/ACN 
 
3.2.6.3 Data analysis 
 
The results were exported with the Mascot algorithm using the SwissProt database on a 
ProteinScape 3.0 workstation. The search parameters were as follows: Taxonomy- Homo 
Sapiens and Viruses; Enzyme-trypsin; Missed cleavages-1; Fixed modification- 
carbamidomethyl (C); Variable modification- oxidation (M); Precursor tolerance-50 ppm; 
Fragment tolerance-0.7 Da. The identities of the m/z ions detected in MALDI IMS were 




3.2.7 Panther and network analysis 
The PANTHER (Protein Analysis THrough Evolutionary Relationships) 
(http://pantherdb.org/) gene ontology classification system was used to annotate and 
cluster the proteins according to molecular function and pathways. The retrieval of 
interacting genes/proteins (STRING) database (http://string-db.org/) was used to 
determine the physical and functional interactions among the identified proteins. 
STRING defines a metric called “confidence score” to define interaction confidence. 
Interactions with a highest confidence score of≥ 0.9 were viewed.  
3.2.8 Immunohistochemistry of p24 and Heat Shock 70 Proteins 
The detection of p24 was performed on the MALDI IMS samples while heat shock (Hsp) 
70 protein was also detected in a separate cohort of DLBCL samples (Appendix J). 
3.2.8.1 Antigen retrieval step 
FFPE tissue sections placed on coated slides were dewaxed and cleared prior to boiling in 
appropriate buffer (Table 3.2) in a pressure cooker for 90 sec.  They were then left to 
stand in the buffer for a further 20 min to allow for cooling before washing with distilled 
water.  
3.2.8.2 Immunohistochemistry 
Following antigen retrieval, the slides were then washed with distilled water prior to 
incubation with 3% hydrogen peroxide for 10 min.  This was followed by washing in 
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PBS-Tween (0.02 % v/v) for 10 min before blocking with goat serum (5% in PBS) for 15 
min.  The tissue slides were then incubated with primary antibody (Table 3.2).  The 
primary antibody was then washed in PBS-T and the tissue incubated with the Envision 
anti- mouse HRP labelled polymer for 30 min. This was then followed by incubation for 
10 min with DAB to stain the antibody- antigen complex. The tissue slides were then 
counterstained with Mayers Haematoxylin, and mounted with DPX.  










EDTA, pH 9 

















3.2.8.3 Assessment of immunohistochemical stains 
 
Immunopositivity of p24 in lymphoid tissue was considered when mononuclear cells, 
macrophages or the meshwork of follicular dendritic cells were staining (Moonim et al. 
2010). Immunopositivity of Hsp70in tumour cells was evaluated by determining the 
proportion of cells staining for Hsp70 as well as the intensity of the stain. Staining 
intensity was graded as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong); percentage 
of positive cells examined was scored as 0 (negative), 1 (< 10%), 2 (10-25%), 3 (25-





3.3.1 MALDI IMS analysis results 
The representative protein profile of control lymph node and DLBCL were characterised 
using the histology-directed MALDI IMS approach. Mass spectra from the ROIs in 
follicular regions of reactive nodes as well as tumour sections of DLBCL (Appendix C) 
were extracted and statistically compared using Clinprotools software. There were thirty
five different mass ions that were differentially expressed between reactive node spectra 
and DLBCL as well as between DLBCL subtypes. However, only twenty five peptides 
were successfully identified using nLC-MS/MS (Appendix K).  
3.3.1.1 Proteins differentiating between reactive nodes and DLBCL in the HIV 
negative cohort 
 The peak picking function identified twenty peptides in the range of m/z 700- 2000 that 
were differentially expressed between the reactive nodes and DLBCL cases (Table 3.3). 
Fifteen (15/20) of these peptides were successfully identified using nLC/MS (Table 3.3). 
Nine peptides were upregulated in DLBCL cases including ribosomal protein L40 (m/z 
1039), annexin A5 (m/z 1105) and histone H2A (m/z 944). The majority of the identified 
proteins were downregulated in DLBCL samples including enolase (m/z 704), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (m/z 805) and histone H3 (m/z 
1032).  
GAPDH (m/z 805) was found to be highly expressed throughout the reactive node but 
had moderate expression in the tumour region of HIV negative DLBCL, with some 
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regions having little or no expression of GAPDH (Figure 3.1). In contrast, in HIV 
positive samples, GAPDH was highly expressed throughout the reactive node and tumour 
samples (Appendix O). Histone H3 (m/z 1032) was highly expressed only in the follicular 
region and had very little expression throughout the tumour region of HIV negative 
samples (Figure 3.1). Some expression of histone H3 was also observed in the venules of 
the fatty layer (Figure 3.1). Similar results were observed for the HIV positive samples 
(Appendix O).  
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Table 3.3: Proteins differentially expressed between reactive nodes (RN) and DLBCL 
tissues in the HIV negative cohort. 
 
Ion mass Regulation 
pattern 
Identity Common name 
703.5155897 Down   
704.5124537 Down ENOA_HUMAN Enolase 
713.5527754 Up H4_HUMAN Histone H4 
788.6839193 Down H31T_HUMAN Histone H3 
789.6806242 Down RS16_HUMAN Ribosomal 
protein S16 
801.6711308 Up   
805.6951772 Down G3P_HUMAN GAPDH 
849.6560995 Up   
861.2877784 Up   
927.7955744 Down ALBU_HUMAN Albumin 
944.7990104 Up H2A3_HUMAN Histone H2A 
945.7859354 Up H2A3_HUMAN Histone H2A 
966.7704072 Up   
1032.899619 Down H31T_HUMAN Histone H3 
1039.815191 Up RL40_HUMAN Ribosomal 
protein L40 
1105.856544 Up ANXA5_HUMAN Annexin 5 
1199.120245 Down HSP7C_HUMAN Heat shock 
protein 70 
1287.158619 Down IGHG1_HUMAN Ig gamma-1 
chain C region 
1506.326079 Down KPYM_HUMAN Pyruvate kinase 
1792.315581 Down ACTG_HUMAN Actin 
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Figure 3.1: The distribution of selected peptides from representative samples of the HIV 
negative cohort. GAPDH (m/z 805) was highly expressed throughout the reactive node 
and moderately expressed in the tumour of DLBCL. Histone H3 (m/z 1032) was highly 








3.3.1.2 Proteins differentiating between reactive nodes and DLBCL tissues in the 
HIV positive cohort 
 
The peak picking function identified twenty five statistically significant peptides that 
were differentially expressed between reactive nodes and DLBCL from HIV positive 
patients (Table 3.4). The identity of twenty peptides was successfully determined using 
nLC-MS and matched to various proteins. Fourteen (14/25) of these peptides were 
upregulated and eleven were downregulated. Most of these proteins were also expressed 
in the HIV negative cohort (Table 3.3). There were new proteins which were not 
identified in the HIV negative context including collagen (m/z 848), albumin (m/z 927) 
and heterogeneous nuclear ribonuclear protein A2 (m/z 1378). There were some proteins 
which were regulated in a similar manner as in the HIV negative context including 
annexin A5 (m/z 1105) and histone H4 (m/z 713). However, other proteins were regulated 
differently to the HIV positive context. For example, constitutive heat shock protein 70 
(m/z 1199) was downregulated in the HIV negative cohort but upregulated in the HIV 
positive cohort. Similarly, histone H3 (m/z 1032) was downregulated in the HIV negative 
context but upregulated in the HIV positive context (Table 3.4).  
The distribution of ribosomal protein S16 (RPS16) (m/z 789) and heat shock protein 
(Hsp) 70 (m/z 1199) in HIV positive samples are shown in figure 3.2. RPS16 (m/z 789) is 
expressed throughout the reactive nodes, while it is expressed in a subset of tumour cells 
(Appendix O, Figure 3.2). In contrast in HIV negative samples, RPS16 was only 
expressed in follicular regions of reactive nodes. In addition, it was expressed in some 
tumour cells as well as the venules in the fatty layer (Appendix O). In contrast the ion m/z 
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1199 is expressed in the follicular regions only and diffusely expressed in the tumour 
region (Figure 3.2, Appendix O). Similar results were observed in the HIV negative 
group.  
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Table 3.4: Proteins differentially expressed between RN and DLBCL cases of the HIV 
positive cohort. 
Ion Mass Regulation 
pattern 
Identity Common name 
788.727194 Up H31T_HUMAN Histone H3 
789.721836 Up RS16_HUMAN Ribosomal protein S16 
801.739062 Down 
805.739438 Down G3P_HUMAN GAPDH 
806.729231 Down ENOA_HUMAN Enolase 
816.723438 Down H2B1K_HUMAN Histone H2B 
848.716095 Down COA62_HUMAN Collagen 
849.719735 Down 
850.760654 Down H2A3_HUMAN Histone H2A 
898.807199 Up RL15_HUMAN Ribosomal protein L15 
927.841058 Down ALBU_HUMAN Albumin 
928.805379 Up 
929.809243 Up 
944.860026 Up H2A3_HUMAN Histone H2A 
945.84584 Up H2A3_HUMAN Histone H2A 
957.859394 Up RL13_HUMAN Ribosomal protein L13 
966.844867 Up 
976.809754 Down ACTG_HUMAN Actin 
1032.93542 Up H31T_HUMAN Histone H3 
1039.88407 Up RL40_HUMAN Ribosomal protein L40 
1105.93637 Up ANXA5_HUMAN Annexin A5 
1199.16965 Up HSP7C_HUMAN Heat shock protein 70 
1350.14995 Down RL15_HUMAN Ribosomal protein L15 
1378.17787 Up ROA2_HUMAN heterogeneous nuclear 
ribonucleoproteins 
1792.39323 Down ACTG_HUMAN Actin 
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Figure 3.2: The distribution of selected ions in representative samples of the HIV positive 
cohort’s tissues. Ribosomal protein S16 (m/z 789) and Hsp 70 (m/z1199) were highly 
expressed in germinal centres and a subset of tumour cells. 
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Differences between DLBCL from HIV negative and HIV positive cases were confirmed 
comparing spectra from the two groups. The peak picking algorithm generated seventeen 
peptides that were similar to the peptides identified in the previous comparison sets 
(Table 3.5). 
Some peptides were still upregulated in the HIV positive DLBCL such as histone H3 (m/z 
1032), collagen (m/z 848) and annexin A5 (m/z 1105), while there were other ions which 
had a change in the pattern of regulation when compared to HIV negative DLBCL 
samples. GAPDH (m/z 805) was downregulated in the HIV positive group vs. reactive 
nodes, but was upregulated in the HIV positive group vs. HIV negative group (Table 3.5). 
Similarly, the histone proteins H2A (m/z 945), H4 (m/z 713) were upregulated in both 
DLBCL groups vs. RN but were downregulated in the HIV positive DLBCL group vs. 
HIV negative group.  
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Table 3.5: Differentially expressed proteins between DLBCL tissues from HIV negative 
and HIV positive patients. 
Ion Mass Regulation 
pattern 
Identity Common name 
713.5709 Down H4_HUMAN Histone H4 
788.6688 Down H31T_HUMAN Histone H3 
789.6591 Up RSL16_HUMAN Ribosomal protein 
L16 
801.6639 Down 
805.6682 Up G3P_HUMAN GAPDH 
816.6507 Down H2B1K_HUMAN Histone H2B 
848.63 Down CO6A2_HUMAN Collagen 
849.6382 Down 
850.675 Down H2A3_HUMAN Histone H2A 
944.7813 Down H2A3_HUMAN Histone H2A 
945.7534 Down H2A3_HUMAN Histone H2A 
957.7765 Up RL13_HUMAN Ribosomal protein 
L13 
966.7574 Down 
1032.847 Up H31T_HUMAN Histone H3 
1039.79 Down RL40_HUMAN Ribosomal protein 
L40 
1105.809 Up ANXA5_HUMAN Annexin A5 
1199.082 Up HSP7C_HUMAN Heat shock protein 
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3.3.1.3 Proteins differentiating between DLBCL subtypes 
The presence of the two clustering groups in the PCA analyses of the DLBCL cohorts 
(Appendix H) prompted the comparison of the immunohistochemical subtypes of 
DLBCL. The cases were classified into GC and non-GC using the Hans classification 
algorithm (Appendix D). There were twenty seven differentially expressed peaks 
between GC and non-GC for the HIV negative cohort. Eighteen of these peaks were 
successfully identified which correspond to fifteen different proteins (Table 3.6). The 
majority of the proteins were upregulated in the non-GC subtype including histone 
proteins H4 (m/z 713), H3 (m/z 788), ribosomal proteins S16 (m/z 789) and L40 (m/z 
1039). Downregulated proteins includedcollagen α1(I) (m/z 836), collagen α2 (VI) (m/z 
848), annexin A5 (m/z 1105) and actin (m/z 1792). In addition, unique proteins were 
identified that were not differentially expressed in the other comparison sets including the 
ion m/z 848 belonging to the collagen alpha chain. There were also ions that were not 
differentially expressed in this group including albumin (m/z 927), heterogeneous 
ribonucleoprotein (m/z 1378) and enolase (m/z 704). 
The GC and non-GC comparison set from the HIV positive cohort produced ten 
differentially expressed peaks. We identified nine of these peaks as belonging to seven 
different proteins (Table 3.7). The majority of these peptides were also upregulated in the 
non-germinal centre group, including GAPDH (m/z 805) and heat shock protein 
(m/z1199). Only annexin A5 (m/z 1105) was downregulated in the non-germinal centre 
group vs. the germinal centre in the HIV positive cohort. 
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Table 3.6: Proteins differentially expressed between germinal centre (GC) and non- 
germinal centre (non-GC) DLBCL tissues of the HIV negative cohort. 
Ion Mass Regulation pattern Identity Common name 
713.5531 Up H4_HUMAN Histone H4 
757.6075 Up RL13_HUMAN Ribosomal protein 
L13 
788.6508 Up H31T_HUMAN Histone H3 
789.641 Up RS16_HUMAN Ribosomal protein 
L13 
801.6496 Up 
805.6532 Up G3P_HUMAN GAPDH 
816.6384 Down H2B1K_HUMAN Histone H2B 
836.6418 Down CO1A1_HUMAN Collagenα1(I) 
845.3651 Up 
848.605 Down CO6A2_HUMAN Collagenα2 (VI) 
849.6152 Down 
850.6619 Down H2A3_HUMAN Histone H2A 
861.2948 Up 
898.6963 Down RL15_HUMAN Ribosomal protein 
L13 
940.7182 Up 
944.7667 Up H2A3_HUMAN Histone H2A 
945.7494 Up H2A3_HUMAN Histone H2A 






1032.823 Up H31T_HUMAN Histone H3 
1039.766 Up RL40_HUMAN Ribosomal protein 
L13 
1105.822 Down ANXA5_HUMAN Annexin A5 
1199.041 Up HSP7C_HUMAN Heat shock protein 
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1792.199 Down ACTG_HUMAN actin 
80 
Table 3.7: Proteins differentially expressed between GC and non-GC tissues of the HIV 
positive cohort. 
Ion Mass Regulation pattern Identity Common name 
788.71 Up H31T_HUMAN Histone H3 
789.71 Up RS16_HUMAN Ribosomal protein 
S16 
805.72 Up G3P_HUMAN GAPDH 
928.78 Up 
944.797 Up H2A3_HUMAN Histone H2A 
945.78 Up H2A3_HUMAN Histone H2A 
1032.93 Up H31T_HUMAN Histone H3 
1039.35 Up RL40_HUMAN Ribosomal protein 
L40 
1105.56 Down ANXA5_HUMAN Annexin A5 
1199.16 Up HSP7C_HUMAN Heat shock protein 
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3.3.2 Pathway analysis of differentially expressed peaks 
STRING predicts protein-protein interactions using information gathered from 
experimental and computational sources. PANTHER is a large curated database of 
gene/protein families and their functionally related subfamilies that can be used to 
classify gene/protein lists. The differentially expressed peaks found in the study were 
subjected to further analysis using STRING and PANTHER software in order to further 
understand the identified proteins. The majority of the proteins belonged to pathways 
such as glycolysis, Huntington’s disease, inflammatory pathways mediated by the 
chemokine and cytokine signalling pathways (Figure 3.3). In addition, the proteins were 
found to have a binding function and were involved in the structural integrity of the cell 
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(Figure 3.4). STRING analysis of the differentially expressed proteins identified fourteen 
interactions that formed four clusters (p value = 1.285 e-5). The first cluster included the 
glycolysis pathway proteins consisting of enolase, GAPDH and pyruvate kinase. Enolase 
and GAPDH were also reported to bind to each other (Figure 3.5). The second cluster 
was made up of the ribosomal proteins which are connected to ubiquitin protein by a 
binding, reaction and catalysis interaction. The ribosomal proteins bind and react with 
each other and are collectively involved in catalytic reactions. The third cluster consisted 
of the four histone proteins which bind and react with each other (Figure 3.5). The last 
cluster included the two collagen chains which react together to form collagen. Proteins 
such as annexin A5, albumin and actin did not show any relationship with the other 
protein clusters that were identified in the study (Figure 3.5). 
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Figure 3.3: PANTHER analysis of the pathways associated with the differentially 
































Figure 3.4: PANTHER analysis of the molecular function of the differentially expressed 
peptides/proteins. The majority of the proteins had a binding function. 
Figure 3.5: STRING analysis of all the differentially expressed proteins. The 
relationships between the proteins form four main clusters of glycolytic enzymes, 
ribosomal proteins, histones and collagen. Key: blue-binding, purple- catalysis, black-






















3.3.3 The detection of HIV in DLBCL FFPE tissues 
 
HIV infection plays a role in the pathogenesis and progression of DLBCL tumours 
(Monroe and Silberstein 1995).The presence of HIV in DLBCL samples was detected 
using two approaches. The first approach involved searching viral databases for hits 
using the nLC-MS data from the HIV positive control and tumour samples. The viral 
database searches did not harvest any hits for HIV peptides/ proteins (Appendix L).  The 
second approach involved the detection of the HIV p24 antigen using IHC (Appendix J). 
In addition, we observed negative p24 staining on the majority of control and tumour 
samples (Appendix J). Only one reactive node sample stained positive for p24, which 
was visible in the follicular dendritic network (Figure 3.6), however, no DLBCL sample 
showed any positivity for p24.  
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Figure 3.6: The immunohistochemical staining of p24 in the negative control (A) and 
monocuclear and macrophages in the positive control (B). p24 staining in the follicular 
dendritic network of a HIV positive lymph node (D). All DLBCL samples were negative 





3.3.4 Confirmation of the expression pattern of heat shock protein 70 
3.3.4.1 Expression of Hsp70 in DLBCL tissues 
In order to validate the expression of proteins detected from the MALDI IMS data, IHC 
was performed to detect one of the thirty five proteins identified in the study (Hsp70). 
Hsp70 was chosen because it was one of the proteins which had a differential expression 
pattern across the comparison groups (Table 3.3 vs. Table 3.4). Hsp70 expression was 
detected in 52 samples including the ten samples used in the MALDI IMS analysis 
(Appendix J). Only eleven DLBCL samples were positive for Hsp70 expression which is 
evident by the cytoplasmic staining (Table 3.8). The majority (41/52) of the samples were 
negative for Hsp70 expression; however, some of them (23/41) expressed Hsp70 in 
plasma cells (Table 3.8, Figure 3.7). All the B-cells in the reactive nodes included in the 
confirmation cohort were also negative for Hsp70 expression, however, Hsp70 was 
expressed in the plasma cell (Figure 3.7, Table 3.8, Appendix J). The HIV positive 
DLBCL group had a higher percentage of cases expressing Hsp70 than the HIV negative 
DLBCL group (31.25% vs. 20.7%). In the HIV positive cohort, there were equal numbers 
of Hsp70 expressing cases for both GC and non-GC subtype (40% vs. 40%). In contrast, 
the non-GC subtype in the HIV negative cohort had higher percentage of cases 





Figure 3.7: The control tissue used in the detection ofHsp70 expression was both normal 
gastric (A, B) and cancer tissue (D, E). DLBCL samples show Hsp70 staining in tumour 










3.3.4.2 Correlation of Hsp70 expression with patient outcome 
The effect of Hsp70 expression in DLBCL tissue samples was evaluated using a 
Fischer’s exact test. Hsp70 expression significantly associated with outcome in HIV 
negative DLBCL cases (p = 0.033) (Table 3.8) with Hsp70 positive cases having a worse 
outcome/prognosis (Appendix N). There was no sign association between hsp70 and 
outcome in both HIV positive DLBCL cases and with the combined DLBCL groups (P > 
0.05). In addition, there was no association betweenHsp70 expression in plasma cell and 
outcome (Appendix N).  
Table 3.8: A summary of the Hsp70 IHC results. Hsp70 expression was correlated with 
outcome (alive or dead following treatment) in HIV negative DLBCL (DLBCL -) and 
HIV positive DLBCL cases (DLBCL +) 
Total (N) Hsp pos %  Hsp pos Hsp neg 
(plasma cell) 
Correlation with 
outcome (P value) 
DLBCL- 29 6 20,68966 22 (7) 0.033 
GC 6 1 16,66667 5 (1) 
non-GC 13 4 66,66667 8 (4) 
Unknown 
subtype 
10 1 16,66667 9 (2) 
RN 5 0 0 5 (3) 
DLBCL+ 16 5 31,25 11 (2) 1 
GC 5 2 40 3 (1) 
non-GC 7 2 40 5(1) 
Unknown 
subtype 
4 1 20 3 (0) 
RN 2 0 0 2 (2) 





3.4.1 MALDI IMS analyses of differentially expressed proteins 
 
The differentially expressed peptides in the MALDI IMS analyses were not all identified 
using nLC-MS due to several reasons. The identification of ions generated by MALDI 
IMS has been recently initiated and 100% identification has not yet been achieved 
because of technical differences between the MALDI and nLC- MS techniques (Djidja et 
al. 2010; Schober et al. 2011; Schey et al. 2013). The nLC-MS generates and identifies a 
higher number of ions compared to MALDI-MS due to chromatographic separation and a 
more efficient fragmentation (Gustafsson et al. 2012).  
Further, the matches established from MALDI and nLC may not be accurate, since 
multiple peptides can be linked to one particular ion/ mass. However, some of the 
peptides identified such as those belonging to histone H2A (m/z 944), histone H3 (m/z 
1032) and actin (m/z 1790) have exact matches have been previously observed in other 
studies, thus increasing our confidence in the matches (Djidja et al. 2009; Cole et al. 
2014).  
 
In our study, the majority of proteins that were identified belonged to pathways such as 
glycolysis and the integrin signalling pathway (Figure 3.4) and had a binding and 
structural activity function (Figure 3.3), which again confirms previous findings 
(Álvarez-chaver et al. 2014; Hwang et al. 2007). The glycolytic pathway enzymes 
included GAPDH, enolase and pyruvate kinase (Berg et al. 2002). GAPDH converts 
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glyceraldehyde-3-phosphate to1,3-diphosphoglycerate while enolase-α catalyses the 
dehydratation of 2-phosphoglycerate to phosphoenolpyruvate. The third glycolytic 
enzyme, pruvate kinase transfers a phosphate group from phosphoenolpyruvate to ADP, 
thus producing pyruvate (Diaz-Ramos et al. 2012). The glycolytic pathway proteins are 
frequently overexpressed in cancer due to the high energy requirements of the 
proliferating cancer cells (Tang 2012; Marín-Hernández et al. 2011). However, these 
proteins were shown to be downregulated in our tumour cohort compared to reactive 
nodes. This is probably due to the fact that the follicular region of reactive nodes have 
high rate of proliferating B cells which require more energy. In addition, DLBCL arises 
from the later stages of B cell development, where the proliferation rate of B cells may 
have decreased (Evans & Hancock 2003; Rickert 2013; Basso & Dalla-favera 2015). It is 
also possible that these proteins may not be playing a role in tumour-genesis. 
The glycolytic enzymes have other functions not related to their roles in energy 
generation. Enolase functions as a plasminogen receptor, concentrating proteolytic 
plasmin activity on the cell surface of hematopoietic and endothelial cells, suggesting that 
it may play an important role in regeneration, immune response, and metastasis (Pancholi 
2001; Diaz-Ramos et al. 2012; Kumari & Malla 2015). Downregulation of enolase in 
DLBCL compared to normal tissue (Table 3.3- Table 3.4) may also be a result of the 
cancer cells evading immune surveillance as high concentrations of enolase elicit an 
immune response (Kumari & Malla 2015).Furthermore, the downregulated in enolase we 
observed contradicts other cancer studies which show an upregulation of enolase which 
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result in invasion and also provides protection against therapy (Capello et al. 2011; Song 
et al. 2014; Hsiao et al. 2013).  
 
 GAPDH, another glycolytic enzyme is involved in several cellular processes such as, 
apoptosis and proliferation. Depending on whether it is expressed in the nucleus or 
cytoplasm, it may promote apoptosis or proliferation (Barbini et al. 2007). 
Overexpression in the nucleus promotes apoptosis whilst expression in both nuclear and 
cytoplasmic compartments  promotes proliferation (Barbini et al. 2007). The upregulated 
GAPDH in HIV positive DLBCL may promote tumour-genesis, however this assertion 
requires further investigations with regard to the specific location of GAPDH expression 
(Table 3.3, Table 3.4). Our findings from the distribution of GAPDH (m/z 805) show an 
intense expression in germinal centres and moderate expression in DLBCL tumours 
(Figure 3.1). The heat map intensity profile generated from our study confirms previously 
published data generated by the protein atlas project. The protein atlas project showed 
intense staining of GAPDH in lymph node and low to moderate expression in NHL 
tumours which confirms our findings (Pontén et al. 2008; Uhlén et al. 2005).  
 
A study by Chiche et al (2014) overexpression GAPDH is associated with aggressiveness 
and vascularisation of non-Hodgkin’s lymphoma via a HIF-1 induction by NF-kB. This 
may be a possible reason for the overexpression of GAPDH in HIV positive DLBCL 
tumours compared to HIV negative tumours (Table 3.5), which are highly vascularised 
(Chiche et al. 2014; Liapis et al. 2013). GAPDH was also overexpressed in the non-
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germinal centre subtype (Table 3.6, Table 3.7), which has a constitutively active NF-KB 
pathway, thus suggesting a mechanism for the aggressiveness of this subtype (Davis et al. 
2001).  
Moreover, GAPDH has a protective role against HIV infection and this is perhaps why 
there is increased expression in HIV positive tumour cells. Kishimoto et al (2012) 
observed that viruses produced from cells overexpressing GAPDH showed decreased 
infectivity and reverse transcription efficiency (Kishimoto et al. 2012). 
 
STRING analyses from our study suggest that enolase and GAPDH function by binding 
to each other (Figure 3.5). A few studies observed the binding of enolase and GAPDH 
regulates host-pathogen interaction in bacterial walls (Antikainen et al. 2007). In 
addition, this binding activity is also observed in renal epithelial cells where it regulates 
salt reabsorption (Renigunta et al. 2011). 
 
Pyruvate kinase is the other glycolytic enzyme identified in our study. It is expressed in 
mammalian tissues as four different isozymes: L, R, M1 and M2 (Gupta & Bamezai 
2010). Our study identified the molecular ion m/z 1506 as belonging to either pyruvate 
kinase M1 or pyruvate kinase M2, which share high homology (Table 3.3). The 
downregulation of pyruvate kinase observed in HIV negative DLBCL tumours compared 
to normal tissues, confirms the findings from other studies which reported 
downregulation of pyruvate kinase in gastric and colorectal cancer (Yoo et al. 2004; 
Martinez-balibrea et al. 2009; Israelsen & Vander 2015) These results suggest that the 
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tumours may be channelling glucose to other biosynthetic pathways to synthesize 
nucleotides and other molecules (Israelsen & Vander 2015) .  
Another protein identified in this study was heat shock protein 70 which acts as a 
molecular chaperone. Chaperones can either assist in protein folding or direct misfolded 
proteins for the ER-associated proteosomal degradation system (Muller et al. 2013; 
Young et al. 2003). The Hsp70 proteins bind to misfolded proteins during translation or
after stress-mediated protein damage (Patterson & Hohfeld 2006) by recognizing short 
segments of hydrophobic amino acids flanked by basic residues in substrate peptides 
(Patterson & Hohfeld 2006). The human Hsp70 family consists of at least eight highly 
homologous members that differ by intracellular localization and expression pattern 
(Rohde et al).  The two ubiquitously expressed Hsp70 proteins include, the constitutively 
active Hsp70 (Hsc) and the inducible form (Hspi) (Rohde et al. 2005). In our study the
constitutively active form of Hsp70 was identified by nLC to correspond to m/z 1199 
(Table 3.3, Appendix K). Most IHC antibodies detect both HSP isoforms since they have 
high sequence similarity (Wehner et al. 2003; Leopardi et al. 2001; Qi et al. 2005).  
 Hsp70 expression affects tumour cell survival through the inhibition of the apoptotic 
process (Rohde et al. 2005; Tanaka et al. 2014). Hsp70 has also been shown to affect 
transcription factors involved in the expression of the Bcl-2 family such as p53 thereby 
interferes its function (Goloudina et al. 2012). The upregulation of Hsp70 in normal 
tissue of HIV negative patients may be due to the high proliferation of B cells as well as 
the constant protein synthesis required B cell development (Table 3.3). The 
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downregulation of Hsp70 in DLBCL samples compared to control in the HIV negative 
cohort may suggest that this particular isoform may not be important for the development 
and progression of cancer. However, other forms of Hsp70 may be overexpressed in this 
context (Murphy 2013; Rohde et al. 2005). In addition, the upregulation of this isoform 
of Hsp70 in HIV positive DLBCL samples may suggest that it has an important role in 
the development and progression of cancer in these patients.
Ribosomal proteins were also identified and in conjunction with ribosomal RNA, make 
up the ribosome which is involved in protein synthesis (Bhavsar et al. 2010; Shenoy et al. 
2012). There are eighty different types of ribosomal proteins that make up the subunits of 
the ribosome (Zhou et al. 2015). The biogenesis of the ribosome as well as protein
translation are finely coordinated and essential for cell growth, proliferation and 
differentiation. Interruptions in any of these two cellular processes can severely retard 
cell growth and perturb development (Zhou et al. 2015). Cellular stress resulting from 
nutrient deficiency and toxic chemicals can result in an accumulation of ribosomal 
proteins in the cytoplasm. These ‘ribosome- free’ proteins then stimulate immune 
signalling or tumour-genesis (Zhou et al. 2015).  
Ribosomal proteins have been observed to be upregulated in various tumours and cell 
lines (Henry et al. 1993; Kreunin et al. 2007; Mao-de & Jing 2007) and are said to be 
involved in the progression of colorectal ,oesophageal and gastric cancer (Wang et al. 
2006).  Our study showed that the specific ribosomal proteins were differentially 
regulated depending on the subtype (Table 3.3-Table3.6). While most were 
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downregulated in DLBCL tumours, there were specific subtypes which were upregulated 
in tumours.  Similarly, the majority of ribosomal proteins were upregulated in the non-
GC subtype of DLBCL yet some subtypes were downregulated. This data supports the 
study by Kasai et al (2003) which observed a differential regulation of ribosomal protein 
subtypes in normal and colorectal tumours. 
Abnormal levels of RPL13a in humans interfere with the cell cycle thus inducing 
apoptosis (Chen & Ioannou 1999). In our study, RPL13 was overexpressed in both HIV 
positive DLBCL cases and the non-GC subtype of the HIV negative group suggesting a 
role in tumour aggressiveness (Table 3.4-Table 3.6).RPS16 was downregulated in HIV 
negative DLBCL but upregulated in HIV positive tumours (Table 3.3-Table 3.5). The 
distribution of RPS16 (m/z 789) in DLBCL (Figure 3.2), which was also upregulated and 
concentrated in non-germinal centre subtypes, suggests that not all tumour cells express 
this protein. The human protein atlas also showed a low to moderate cytoplasmic staining 
of RPS16 in NHL cases indicating inter- tumour and intra-tumour heterogeneity (Pontén 
et al. 2008; Uhlén et al. 2005).  
 
Ubiquitin (Ub), which was identified to be fused to a ribosomal protein (RPL40) in our 
study, is a highly conserved protein comprised of 76 amino-acid residues with diverse 
intracellular activities (Patterson & Hohfeld 2006). In humans the Ub genes, Uba80 
(HUBCEP80) and Uba52 (HUBCEP52) encode Ubprotein fused to the ribosomal 
proteins S27a (RPS27a) and L40 (RPL40), respectively (Han et al. 2012). The STRING 
analyses suggest that Ubiquitin binds to ribosomal proteins therefore, indicating the 
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ubiquitin-fusion proteins (Figure 3.3). Our study identified RPL40 to be upregulated in 
HIV negative tumours but downregulated in HIV positive tumours (Table 3.3, Table 3.5). 
It was also overexpressed in the non-GC subtype of DLBCL in both HIV negative and 
positive contexts (Table 3.6, Table 3.7).These results are similar to other reports which 
show an overexpression of RPL40 and RPS27a  in cancer inferring a role in tumour-
genesis and tumour aggressiveness (Barnard et al. 1995; Mafune et al. 1991).  
STRING analysis show that Ubiquitin also binds to Hsp70 (Figure 3.5), and this is 
signified via the ubiquitin-like (UbL) protein binding to the ATPase domain of the 
Hsp70-like Stch protein  in yeast (Kaye et al. 2000)-.  
Collagen is an abundant structural protein comprises one third of the total protein in 
humans. Twenty-eight different types of collagen composed of at least 46 distinct 
polypeptide chains have been identified in vertebrates (Shoulders & Rainers 2010). Its 
fundamental structural unit is a long (300-nm), thin (1.5-nm-diameter) protein that 
consists of three coiled subunits of two α1 (I) chains and one α2 (I) chain (Lodish et al. 
2000). 
Our findings showed that collagen chains, α1 (I) and α2 (VI) were downregulated in 
DLBCL tumours compared to normal tissues of the HIV positive group as well as in the 
non- GC subtype of the HIV negative group (Table 3.3-Table 3.5). Both of these groups 
have a poor prognosis and this may be related to a less responsive host immune system 
(Staudt & Dave 2005; Rosenwald et al. 2002). Collagen has been previously detected as a 
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potential biomarker for DLBCL in the molecular profiling study by Rosenawald et al 
(2002). It was shown to be associated with a ‘lymph node signature’, which indicated a 
host immune response and was indicative of a good prognosis (Staudt & Dave 2005). In 
addition, the collagen genes COL1A2 and COL4A1 were downregulated in advanced 
stage DLBCL (Nishiu et al. 2002) thus confirming upregulated collagen expression being 
a marker for good prognosis. In addition, some DLBCL tumours are heavily infiltrated 
with macrophages, thus leading to increased expression of collagen, since macrophages 
secrets collagen VII, (Staudt & Dave 2005; Schnoor et al. 2008). 
Histone proteins are involved in the packaging of DNA and were observed to be 
differentially expressed in DLBCL. The DNA is hierarchically packed in the nucleus
with the aid of proteins to form a complex called chromatin. The nucleosome core 
particle is composed of two copies of each of histones H2A, H2B, H3 and H4, assembled 
in an octamer with 146bp of DNA wrapped around it (Marino-Ramirez et al. 2005; 
Cohen et al. 2011). While the core histones are highly conserved, there are variants which 
may play role in gene expression and epigenetic silencing (Marino-Ramirez et al. 2005). 
It is the possible that the histones proteins identified in this project may be variants of 
core histones which may have functions in tumour development and progression.  
The core histones have N-terminal tails of variable length that are subject to extensive 
PTMs, which have been implicated in transcriptional activation, silencing, chromatin 
assembly and DNA replication (Marino-Ramirez et al. 2005). The specific PTMs can 
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either repress or activate gene expression. Ubiquitination of histone H2A on lysine K119 
and methylation of lysine 27 on histone H3repress genes while methylation of histone H3 
at lysine 4 (H3K4me3) activates gene expression (Ezponda & Licht 2014).  
The various PTMs are regulated by many proteins including histone acetyltransferases 
(HATs), histone deacetylases (HDAC), kinases and histone lysine methyltransferases 
(Bannister & Kouzarides 2011).  
The deregulated activity of the enzymes may play a role in the development of cancer by 
either altering gene expression programmes of oncogenes/tumour suppressor genes, or by 
histone modifications affecting the integrity of the chromosome (Bannister & Kouzarides 
2011). The deregulated activity of chromatin modifiers is particularly linked to cancer 
formation and progression (Ellis et al. 2009; Esteller 2011; Geutjes et al. 2012; Gajer et 
al. 2015). Inhibitors of HAT  and HDAC result in growth arrest, differentiation, and 
apoptosis (Gajer et al. 2015; Lane & Chabner 2009) and are used in clinical trials (Manzo 
et al. 2009).  
 
The various histone protein subtypes are commonly isolated in MALDI IMS 
experiments(Seeley & Caprioli 2008; Djidja et al. 2010; Hardesty et al. 2011)due to a 
technical limitation of MALDI IMS which favours high abundant and soluble proteins 
(Seeley & Caprioli 2011). Proteins such as Hsp70, albumin and GAPDH are amongst the 
most abundant and supports the observation made by Seeley and Caprioli (2008). Histone 
H3 (m/z 1032) had intense, widespread distribution in germinal centres and tumour cells 
(Figure 3.2) which supports the data generated by the atlas protein project in which 
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intense nuclear expression of histone H3 protein is also expressed in germinal centre cells 
and NHL tumours (Uhlén et al. 2005; Pontén et al. 2008). 
 
 
It is encouraging to note that, there are similar proteins differentially expressed between 
normal and tumour of both HIV negative DLBCL and HIV positive DLBCL suggesting a 
similar pathology. However, other proteins such as annexin A5 and albumin, were also 
differentially expressed in our cohort however, the STRING analysis did not find a 
relationship between these proteins and other proteins identified in the study (Figure3.5). 
The differences in albumin levels observed may be due to different levels if serum 
present in the tissue sections (Londoño et al. 1992). However, albumin is decreased in 
both HIV negative and HIV positive DLBCL samples compared to controls (Table 3.3 
and Table 3.4) and not statistically different in the other comparison sets thus, implying 
that this observation is specific to tumour processes and not due to background. 
 
Annexin A5 is a calcium binding protein that is known to play a role in the development 
and progression of various cancers (Deng et al. 2013; Prognosis et al. 2009). An increase 
in annexin A5 has been correlated with advanced stage, metastasis and poor prognosis in 
colorectal cancer, breast and pancreatic cancer (Prognosis et al. 2009; Deng et al. 2013). 
In our study, annexin A5 was increased in DLBCL tumours compared to control tissue 
suggesting a role in the development of the DLBCL. In addition, annexin A5 was 
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decreased in the non-germinal centre subtype, in both HIV contexts, suggesting it may 
have a role in good prognosis.  
3.4.2 The detection of HIV proteins 
It has been postulated that HIV initiates the development of cancer by the chronic 
stimulation of B cells (He et al. 2006; Gloghini et al. 2013a).In order to determine 
whether HIV does this in close proximity to the tumour, the HIV capsid protein, p24, was 
immunohistochemically detected in the MALDI IMS samples. P24 protein was detected 
in the network of follicular dendritic cells of a single reactive node sample (Figure 3.10), 
thus confirming previously published data (Moonim et al. 2010). In addition, a lack of 
expression was to be expected as HIV infects CD4+T helper cells which may be limited 
by the diffuse spread of tumorous B cells (Campo & Rule 2015). Furthermore, there is a 
depletion of CD4 T cells in the region due to HIV infection and lysis (Liapis et al. 2013). 
The viral database search for HIV proteins using the peptide mass list also did not 
produce any match against HIV proteins which is probably due to  ‘silencing’ by other 
abundant proteins. The peptides from all the HIV positive samples were mixed and ran 
on the nLC instrument. If only one sample has the HIV proteins, it is possible that the 
protein quantity may have been insufficient for successful detection.  
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3.4.3 Confirmation of the expression pattern of heat shock protein 70 
There are several aspects of HSP70 function that are important for cancer development 
and progression. At the initial stages of tumour-genesis, Hsp70 can protect cells 
undergoing transformation from oncogenic stress induced by overexpression of 
oncogenes (E.A. Afanasyeva, E.Y. Komarova, L.G. Larsson, F. Bahram, B.A. Margulis 
2007). In addition, Hsp70 has been shown to suppress cellular senescence which is an 
important anti-tumour mechanism at the early stages of tumour-genesis and also 
important in how cancer cells respond to therapy (Sherman et al. 2007). Hsp70 is an 
essential factor for tumour cell survival and tumour growth. Elevated levels of Hsp70 in 
tumours correlate with poor prognosis and higher resistance to cancer treatment for 
cancer patients (Ciocca & Calderwood 2005). 
It is for these reasons that Hsp70 was chosen as the protein whose expression was going 
to be confirmed in a separate cohort of DLBCL samples. Most of the DLBCL cases did 
not express Hsp70 confirming previously observed data in non-small lung cancer (Qi et 
al. 2005). The lack of Hsp70 expression in the GC cells in RN samples contradicts 
published data where the blast cells were intensely positive (Leopardi et al. 2001). 
Differences in antibodies and IHC conditions may account for the discrepancies. Our 
study utilised a polyclonal antibody while Leopardi used a monoclonal antibody which 
recognise all forms of Hsp70. Interestingly, this is a first report showing Hsp70 
expression in GC plasma cells (Figure 3.7, Appendix J). It is therefore possible that the 
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expression in plasma cells may be the responsible for the expression of Hsp70 in the 
samples used in MALDI IMS (Figure 3.2). In addition, HIV infected tumours express 
high levels of plasma cells (Liapis et al. 2013), and this may explain the higher Hsp70 
expression levels in the HIV positive cohort (Table 3.8). Interestingly equal proportion of 
GC and non-GC subtypes expressed Hsp70 in the HIV positive cohort, contrasting with 
the MALDI IMS analysis results (Table 3.3). However, the sample size used in the study 
may not give representative results. The Hsp70 expression levels in the non-GC subtype 
suggest that Hsp70 may be involved in treatment resistance (Fang et al. 2013; Carbone & 
Gloghini 2014), since high levels of Hsp70 inhibit apoptosis and promote apoptosis (Qi et 
al. 2005; Liu et al. 2011; Mjahed et al. 2012). The GC subtype expresses high levels of 
BCL-2 to inhibit apoptosis (Shaffer et al. 2002). However, Hsp70 has been shown to 
stabilise BCL-2 under oxidative stress (Jiang et al. 2011). It is possible that Hsp70 and 
BCL-2 work concertedly to inhibit apoptosis and promote proliferations of DLBCL GC 
tumours.  
In summary, Hsp70 was overexpressed in HIV positive samples of control and tumour 
samples as well as in the non-GC subtype of DLBCL in the HIV negative cohort, thus 
confirming the MALDI IMS data (Table 3.8).  
 
The expression of Hsp70 was correlated with survival where Hsp70 expression signified 
a poor prognosis in the HIV negative group but not in the HIV positive group (Table 3.8, 
Appendix N). Patients with Hsp70 expression in tumour cells either relapsed after 
treatment or died during treatment (Appendix F), thus confirming its role in 
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chemotherapy resistance (Liu et al. 2011; Fang et al. 2013). The study had a lower 
number of HIV positive sample and the prognostic significance of Hsp70 in this group 
may increase with a larger sample size. In addition, no correlations with clinic-biological 
features were possible due to only eleven samples being positive (Table 3.8).  
 
The study was met with a few limitations which were unavoidable. The MALDI IMS 
analysis had a low sample size due to the high expense of this technique; which was 
increased during the Hsp70 IHC analysis. However, the sample size of this cohort also 
decreased due to lack of Hsp70 expression in a substantial amount of the samples (Table 
3.7). In addition, the study samples were varied in terms of tissue origin as well as in 
basic clinical characteristics thus increasing the variation. This was unavoidable as the 
study population also differed in some clinical characteristics and contained mostly 
extranodal DLBCL cases (Chapter 2) which would diversify the tissue origin. We also 
encountered technical  limitations that are inherent to the MALDI IMS machinery such as  
low resolution and detection of abundant proteins (Seeley & Caprioli 2011).Finally, the 
study was limited by using only one protein to confirm the MALDI IMS data, which 
lowered the sensitivity and specificity as previously published (García-Bilbao et al. 
2012).  
In summary, the study identified proteins such as the histones, GAPDH, Hsp70 and 
ribosomal proteins, to discriminate between normal and DLBCL tumour, as well as 
between DLBCL subtypes. Furthermore, these proteins were identified in all DLBCL 
cases irrespective of HIV status, suggesting that DLBCL tumour-genesis is similar 
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between the two cohorts. The expression pattern of one of the proteins, HSP70, was 
confirmed by immunohistochemical staining using a separate cohort of cases. Expression 
of Hsp70 was correlated with worse prognosis in HIV negative DLBCL cases but not 





CHAPTER 4: CONCLUSIONS AND FUTURE 
RECOMMENDATIONS 
DLBCL is divided into prognostically significant groups using the IPI. However, this is 
not able to sufficiently classify all patients, and does not highlight potential therapeutic 
targets. There are various molecular markers for DLBCL, which are not used clinically 
due to sensitivity and specificity issues. However, these have assisted in advancing 
knowledge on the development and progression of the disease. These have not been 
studied in the HIV context, therefore leading to a lack of understanding on the molecular 
pathology of the disease. The aim of the study was to determine biomarkers for HIV and 
non- HIV related diffuse large B cell lymphoma. The specific objectives of the study 
included: 
1. Determining differences in the clinicipathologic features of HIV negative and
HIV positive DLBCL.
2. Identifying protein biomarkers for HIV negative and HIV positive DLBCL using
MALDI Imaging MS.
3. Characterizing the identified proteins using LC-MS/MS.
4. Correlating the resulting molecular data with clinicopathological information.
The study showed that DLBCL from HIV negative and HIV positive patients presents in 
a clinically similar manner except for differences in median age and frequency of 
elevated LDH levels, thus suggesting possible similarities in lymphomagenesis pathways 
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between the two cohorts. In addition, the study identified potential clinical biomarkers 
that may be used for prognosis in addition to current prognostic indicators. Two of the 
clinical parameters were indicative of good prognosis while the other two were indicative 
of worse prognosis.  The study may have been limited by record keeping and 
confounding, yet the prognostic markers highlighted herein have been previously 
identified by other studies. In addition, some of them form part of the IPI thus confirming 
their legitimacy. These clinical biomarkers were found to be prognostic for all DLBCL 
cases, suggesting that these may be used without the knowledge of the patient’s HIV 
status.  Identical parameters were observed to be prognostic for the HIV negative group, 
with the addition of extranodal tumour site, suggesting that the extranodal site might be 
prognostic. We did not observe statistically significant difference in OS rates between the 
three major extranodal sites of the HIV negative cohort. However, comparisons with the 
other less frequently detected extranodal sites might shed more light. We were not able to 
determine prognostic factors specific for the HIV positive group due to low sample size. 
This group was smaller than the HIV negative group and with the added complication of 
missing information, resulted in non-significant prognostic indicators.   
 
This study also identified protein biomarkers for both HIV negative DLBCL and HIV 
positive DLBCL including clusters of inter-connected proteins differentially expressed 
between the two cohorts. These included glycolytic proteins, histones, ribosomal proteins 
and collagen. These proteins have been previously identified in other cancers by MALDI 
IMS technology, signifying a restriction to identify certain proteins. However, these 
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proteins have been previously shown to have roles in cancer development and 
progression, thus supporting their potency. MALDI IMS is a powerful technology yet it 
is often limited by high costs and numerous pre-analytical steps, however, the data 
presented in this thesis highlights the value it may bring to cancer research.  
 
The identification of similar proteins in HIV negative and HIV positive DLBCL 
highlights the similarities between the two cohorts. However, the proteins were 
sometimes differentially regulated pointing to different roles within each context. 
Therefore, the protein markers identified herein require further studies use as for potential 
therapeutic targets.  
 
The expression of one of the proteins identified, Hsp70, was confirmed using a separate 
cohort of DLBCL samples.  Our results confirm the expression pattern observed in 
MALDI IMS analyses. This substantiates the use of MALDI IMS technology to correctly 
determine the distribution of different molecules or ions within tissues. We showed that 
Hsp70, despite low sample size, has prognostic significance for DLBCL samples.  The 
expression pattern of this protein in DLBCL samples suggests that more studies are 







In conclusion, all the objectives of this project were successfully accomplished. 
Biomarkers for DLBCL were identified including clinical and molecular markers which 
may be used for diagnostic and prognostic purposes.  However, more studies are required 
prior to this. Therefore, future studies would involve: 
1. The confirmation of these results in a multicentre cohort consisting of DLBCL 
cases from HIV negative and HIV positive patients. 
2. The determination of the distribution and prognosis of the other proteins 
identified herein, both individually and in a synchronous manner. 
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APPENDIXA: LINEAR REGRESSION CODES 
 
Codes for Linear 
Regression 
0 1 2 
Survival status Alive Death  
Stage I/II III/IV  
LDH High Normal  
Gender Female Male  
IPI scores 0/1 2/3 4/5 
CD4 count <200 >/=200  
Nodal/extranodal Extranodal Nodal  
B symptoms No B symptoms B symptoms  





































E xtra n o d a l
N oda l
 
Kaplan Meier survival plot of HIV negative DLBCL patients presenting in nodal 

























E x tra n o d a l
 
Kaplan Meier survival plot of HIV positive DLBCL patients presenting in nodal 




APPENDIX C: ROIS DRAWN IN MALDI IMS ANALYSIS 
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APPENDIX D: HAN’S CLASSIFICATION ALGORITHM ANTIBODIES 




Antigen Clone Clonality Supplier Antibody 
dilution 
1mM Tris 1mM 
EDTA, pH 9 
CD10 56C6 Monoclonal Dako 1:40,1 hr 
1mM Tris 1mM 
EDTA, pH 9 
BCL6 PG-B6p Monoclonal Dako 1:20,1 hr 
1mM Tris 1mM 
EDTA, pH 9 
MUM1 MUM1p Monoclonal Dako 1:50,1 hr 
Assessment of immunohistochemical stains 
A qualitative assessment was used to classify cases as positive or negative.  Cases were 
considered positive, if 30%tumour cells were stained with an antibody (Hans et al 2004).
According to the College of American Pathologists guidelines, weak and patchy nuclear 
staining in the tumour was also designated positive.  
131 
Representative of positive stains of CD10, BCL6 and MUM 1 of the Hans 
classification. 
Control Samples 





APPENDIX E: OTHER PROTOCOLS 
Slide coating protocol 
 Mix 1:1 poly-L-lysine with water in an Eppendorf tube
 Add 1 µl of IGEPAL per 1.5 ml
 Streak out 2 drops of a Pasteur pipette onto an ITO coated slide using a
tongue depressor
 Dry slide for 15 min on 60°C
Zip Tip Method 
 Wet Zip tip in 20 µl ACN (aspirating and dispensing 10X)
 Equilibrate zip tip in 20 µl of solvent A (0.1% TFA)
 Bind Sample (2 µl of sample and 8 µl solvent A)
 Wash zip tip in solvent A
 Elute in 10 µl Solvent B ( 50 % ACN; 0.1 % TFA)
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APPENDIX F: COMPOSITION OF SOLUTIONS 
 
Mayers Hematoxylin solution 
 
Haematoxylin                                      1 g 
Potassium/ammonium alumminium  50 g 
Sodium iodate          0,2 g 
Citric acid                   1 g 
Chloral hydrate                                50 g 
Distlled water                                1000 ml 
 
Dissolve the haematoxylin, potassium alumminium and sodium iodate in water.  Add 
chloral hydrate and citric acid.  Boil for 5 min.  Cool and filter. 
Ammoniated water 
 
  Ammonium hydroxide (concentrated)   2 ml 
  Distilled water      1000 ml 
  Mix well. 
Phloxine-eosine solution 
 
1 % Phloxine B                          10 ml 
1 % Eosin Y                                 100 ml 
95 % Alcohol                           780 ml 





APPENDIX G: THE DEMOGRAPHICAL CHARACTERISTICS OF THE PATIENTS 
USED IN MALDI MSI ANALYSIS 
 
 









Mean Age 47.5 40 56.25 39.25 
N 2 2 8 8 
Gender (F/M) 0/2 0/2 5/3 5/3 
Subtype 
(GC/non-GC) 
N/A N/A 4/4 4/4 
Tissue Origin Lymph node Gastric, nasopharynx, soft tissue 
of head and neck, Axilla, lymph 






























PCA analysis of reactive nodes (green) and DLBCL (red) cases in HIV negative 
















PCA analysis of germinal centre (GC) (green) and non- GC (red/maroon) DLBCL 
subtypes in HIV negative (Panel A) and positive (Panel B) cases.  
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APPENDIX I: PANTHER ANALYSIS 
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APPENDIX J: IHC RESULTS FOR ANTI-HSP70 ANTIBODY 
Patient # HIV status DLBCL 
subtype 
Hsp70 p24 Clinical 
outcome 
1 neg RN neg neg N/A 
2 neg RN neg neg N/A 
3 pos RN neg neg N/A 
4 pos RN pos* pos N/A 
5 neg ABC pos neg deceased 
6 neg ABC pos* neg alive 
7 neg GC pos* neg deceased 
8 neg GC neg neg alive 
9 pos ABC neg neg deceased 
10 pos GC pos neg deceased 
11 neg RN pos* ND N/A 
12 neg RN pos* ND N/A 
13 neg ABC pos ND relapsed 
14 neg ABC neg ND alive 
15 neg ABC pos* ND deceased 
16 neg ABC pos ND deceased 
17 neg ABC pos* ND relapsed 
18 neg ABC neg ND deceased 
19 neg ABC pos ND relapsed 
20 neg GC neg ND alive 
21 neg GC pos ND relapsed 
22 neg unknown pos* ND deceased 
23 neg unknown neg ND relapsed 
24 neg unknown neg ND alive 
25 neg unknown pos* ND deceased 
26 neg unkown neg ND alive 
27 neg unkown neg ND relapsed 
28 neg unkown neg ND deceased 
29 neg unkown pos ND deceased 
30 neg unkown neg ND deceased 
31 pos ABC neg ND deceased 
32 pos ABC pos* ND relapsed 
33 pos ABC pos ND alive 
34 pos ABC neg ND alive 
35 pos ABC pos ND deceased 
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36 pos GC pos ND deceased 
37 pos GC neg ND deceased 
38 pos GC neg ND alive 
39 pos unknown neg ND deceased 
40 pos unknown neg ND deceased 
41 pos unknown pos ND deceased 
42 pos ABC neg ND deceased 
43 neg unknown neg ND alive 
44 neg RN pos* ND  
45 neg GC neg ND deceased  
46 neg ABC neg ND deceased 
47 pos GC neg ND deceased 
48 neg ABC pos* ND alive 
49 neg ABC neg ND alive 
50 neg GC pos* ND alive 
51 neg ABC pos* ND alive 
52 pos unknown neg ND alive 

















703.516    
704.51 704.4049 K.GVPLYR.H ENOA_HUMAN 
713.55 714.35 R.TLYGFGG.- H4_HUMAN 









789.7218 789.4083 K.KFGGPGAR.A RS16_HUMAN 
801.739    
805.739 805.43 K.VGVNGFGR.I G3P_HUMAN 
806.729 806.4464 K.YNQLLR.I ENOA_HUMAN 
816.729 816.45 R.EIQTAVR.L H2B1K_HUMAN 
836.64 836.43 R.GPAGPQGP.R CO1A1_HUMAN 
848.716 848.4622 R.FVEQVAR.R CO6A2_HUMAN 
849.72    
850.761 850.5275 R.HLQLAIR.N H2A3_HUMAN 
861.28    
898.81 898.4790 K.QGYVIYR.I RL15_HUMAN 




944.860 944.5346 R.AGLQFPVGR.V H2A3_HUMAN 
945.845 H2A3_HUMAN 
957.85 957.5291 R.TIGISVDPR.R RL13_HUMAN 
966.845 
971.76 
976.81 976.45 K.AGFAGDDAPR.A ACTB 
978.8 
988.73 
1032.93 1032.5988 R.YRPGTVALR.E H31T_HUMAN 
1039.88 1039.5168 K.EGIPPDQQR.L RL40_HUMAN 
1105.93 1106.5737 R.SEIDLFNIR.K ANXA5 
1199.17 1199.6801 K.DAGTIAGLNVLR.I HSP7C_HUMAN 
1287.15 1286.6723 R.EPQVYTLPPSR.D IGHG1_HUMAN
1350.15 1353.7517 K.NKTGAAPIIDVVR.S RL15_HUMAN 
1378.18 1378.63 R.GGGGNFGPGPGSNFR.G ROA2_HUMAN
1506.33 1507.85 R.APIIAVTRNPQTAR.Q KPYM_HUMAN
1792.39 1790.9083 K.SYELPDGQVITIGNER.F ACTG 
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APPENDIX L: THE VIRAL DATABASE SEARCH HITS 
MALDI 
IMS ion 
nLC -MS ion Peptide Sequence Identification (Accession) 
788.727 788.4805 K.KMPLQR.F R1AB_BYVU [Replicase 
polyprotein 1ab (Beet yellow 
virus)] 
944.5346 R.AGLQFPVGR.V R.LEVSAGGRR.N 074L_FRG3G 
[Uncharacterised protein 074L 
(Frog virus 3)] 
976.81 976.45 K.AGFAGDDAPR.A FGR_FSVGR [Tyrosine 
protein kinase transforming 




APPENDIX M: REAGENT SUPPLIERS 
 
Name Supplier 
Trifluoroacetic acid Sigma 
Acetonitrile Merck 
Water, proteomics grade Fluka 
HCCA matrix Bruker 
Ethanol Absolute Millipore 
H2PO4N Sigma 
Trypsin, modified 100 µg Promega 
Zip tip C18 column Merck 
Water, molecular biology grade Sigma 
Acetonitrile Sigma 
Trypsin, modified 100 µg Promega 




Ammonium Bicarbonate Sigma 
ITO coated slides  Sigma 
Xylene  Millipore 
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Ethanol, Absolute Illovo 
Ethanol, proteomics grade Millipore 




Ethanol (crude) Kimix 
Entelin DPX Merck 
Tris Sigma 
EDTA Merck 
PBS tablets Quantum Biotechnologies 
Tween Sigma 
Hydrogen peroxidase Merck 
Envision anti- mouse HRP labelled polymer kit Dako 











APPENDIX N: FISCHER’S EXACT CORRELATION TEST FOR HSP70 
Correlation of hsp70 expression with outcome in ALL DLBCL cases 
Hsp70 alive deceased relapsed 
neg 14 16 4 
pos 1 7 3 
Fischer’s exact test, P= 0.096 
Correlation of Hsp70 expression with outcome in HIV negative DLBCL cases 
Hsp70 alive deceased relapsed 
neg 11 9 3 
pos 0 3 3 
Fischer’s exact test, P= 0.033 
Correlation of Hsp70 expression with outcome in HIV positive DLBCL cases 
Hsp70 alive deceased relapsed 
neg 3 7 1 
pos 1 4 0 
Fischer’s exact test, P= 1.0 
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Correlation of Hsp70 expression in plasma cells (pos*) with outcome in ALL 
DLBCL cases 
Hsp70 alive deceased relapsed 
neg 10 12 2 
pos 1 7 3 
Pos* 4 4 2 
Fischer’s exact test, P= 0.228 
Correlation of Hsp70 expression in plasma cells (pos*) with outcome in HIV 
negative DLBCL cases 
Hsp70 alive deceased relapsed 
neg 7 5 2 
pos 0 3 3 
Pos* 4 4 1 
Fischer’s exact test, P= 0.191 
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APPENDIX O: DISTRIBUTION OF PEPTIDES IN OTHER TISSUES 
The distribution of the selected m/z ions in RN (first panel), non-GC subtype 









RN vs. DLBCL in HIV negative samples  
Mass (m/z) Average spectral counts P Value 
848.6824904 1.640581802 3.25488E-10 
4.621165528 
966.8115383 1.781379787 1.77266E-10 
7.848620903 
849.6895863 2.536168069 1.26326E-08 
4.448123243 
713.5894992 1.566549939 4.81689E-09 
3.764913579 
1199.140513 42.04226872 7.46274E-10 
16.41734753 
944.8332528 12.94403384 2.00549E-10 
57.9598311 
945.8189248 8.555499662 2.79281E-08 
23.40624022 
1105.902484 3.567334432 0.001222306 
9.516735867 
704.5296597 4.433981487 3.30131E-10 
0.958931649 
703.5300794 9.704732021 2.00549E-10 
1.425739457 
816.6952902 1.903373504 3.99985E-06 
3.144055688 
850.7294258 1.932036404 2.79049E-05 
3.070037899 
927.8205705 5.212617163 3.25488E-10 
2.356424317 
801.7069476 2.048129317 1.30734E-06 
3.684781149 
1032.92104 18.63873375 2.73687E-08 
6.674150391 
1039.851656 6.610977244 2.53088E-05 
9.995413492 




805.7201214 4.202738401 0.0003027 
  3.055520977   
789.6996394 6.973311073 2.79049E-05 
  4.024570292   
800.6984832 3.02172035 4.85845E-05 
  1.958786847   
1287.180979 13.05314673 0.000729309 
  8.307209538   
1506.353642 15.781436 0.001770492 
  10.48666049   
898.7809871 2.292654573 0.000795565 
  2.99261064   
861.3485862 1.478005994 0.000348822 
  4.983441684   
1792.36239 19.40193012 0.00119135 
  14.01941369   
957.8393698 3.897666709 0.001921746 
  4.659769973   
788.7046317 13.61064674 8.52279E-37 
  11.88406465   
940.7983161 3.680547966 0.001921746 
  3.968477108   
1350.072 8.229488832 0.002098595 
  8.336123317   
971.8538135 3.432872197 0.002836113 
  3.463089742   
      
RN vs. DLBCL in HIV positive samples   
Mass (m/z) Average spectral counts P Value 
1199.264838 22.57148023 5.83654E-08 
  47.3583536   
928.8523233 3.53048065 2.57665E-09 
  7.470231581   
929.8606054 2.730678081 2.67795E-07 
  4.948219418   
913.870908 2.308478534 6.95571E-08 
  3.885498974   
1039.939009 7.808761889 2.01347E-05 
152 
12.79867059 
955.9166261 3.340607119 2.12542E-05 
5.173299318 
1032.995113 12.47804688 2.48328E-05 
24.77230317 
940.873734 3.66371794 0.00033059 
5.522471635 
957.9176726 3.773143406 0.000827826 
5.877385793 
944.9139686 37.43925397 0.023544877 
53.18901007 
945.901411 19.32856228 0.096060132 
25.5430401 
976.8613064 6.174796667 0.641477291 
4.416680602 
901.8573617 2.82523104 0.020909117 
3.6762631 
806.7813637 2.744360136 0.020909117 
3.519799067 
1350.236044 12.32194462 0.005096781 
15.14775719 
849.767046 5.033143867 0.005526735 
4.204505114 
788.7801803 10.10359859 0.035297695 
13.5359925 
805.7879371 5.212136549 0.118286364 
6.312920751 
801.803695 3.972383905 2.87988E-16 
2.905240387 
789.7732526 4.881943575 0.118286364 
6.03710889 
713.6937518 3.575978626 6.85905E-14 
2.680069239 
816.7791454 3.233234767 0.018723773 
3.655313048 
850.809073 4.049494886 0.014078119 
3.607894566 
848.7712425 3.317296703 0.503438499 
 
 153 
  3.471410596   
927.8931057 4.539180318 0.020442803 
  4.651097341   
      
DLBCL - vs. DLBCL +  
Mass (m/z) Average spectral counts P Value 
848.6744654 4.332166842 6.75016E-14 
  2.391057541   
849.6830213 4.968031645 3.24363E-12 
  3.09719882   
1199.158789 16.09044641 2.02709E-11 
  33.16941282   
966.807324 8.277738486 3.24363E-12 
  5.052465512   
1032.906715 6.940176357 2.22657E-11 
  15.1788371   
816.6916499 3.498571481 3.59153E-06 
  2.581095714   
944.8367432 61.54123199 0.340965291 
  47.43398047   
805.7182447 3.560944407 0.128475832 
  4.429705026   
850.7211837 3.549771263 0.018687064 
  3.036758273   
957.8299739 4.389037793 0.048655014 
  5.065131029   
789.7025559 4.475229145 0.048655014 
  5.194636623   
1105.853231 10.6876101 0.009558436 
  13.74151664   
945.806785 25.75740601 0.390092408 
  21.81732467   
1039.845578 10.99789716 0.068868156 
  10.18944963   
940.7993617 3.988628465 0.044143044 
  3.496476818   
788.7127264 12.51059334 0.690012314 
  11.83853688   
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GC vs. non-GC in HIV negative samples  
Mass (m/z) Average spectral counts P Value 
836.6443385 5.198087328 2.16956E-23 
  1.577030151   
898.7052997 4.491995532 2.16956E-23 
  2.089025364   
852.6430848 3.348912967 4.48957E-20 
  1.370248327   
837.641179 3.136661144 3.18523E-16 
  1.624835295   
850.6666988 4.061525805 8.89692E-15 
  2.061777584   
1105.835641 15.75522758 3.42633E-11 
  7.456601925   
816.6416667 3.964127571 9.91374E-10 
  2.465323664   
1199.061796 7.309773584 4.42146E-08 
  20.77178604   
1032.820831 4.116179079 0.000177643 
  7.239172787   
1127.827176 7.068504182 0.000309293 
  5.448507232   
802.6470153 2.515063014 0.000676255 
  2.041782231   
966.7438184 5.731880095 0.001197052 
  8.184522349   
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957.763857 3.799186508 0.00128222 
4.951484216 
945.7453563 14.83723585 0.002949321 
24.59288367 
944.7675888 31.23194311 0.003071558 
62.35475003 
971.7734707 3.052610511 0.025848861 
3.751043953 
1792.211581 14.80173834 0.029116639 
11.68849907 
940.7149721 2.67508276 0.104815427 
3.479708905 
861.2860225 4.569758427 0.110176874 
3.019012809 
788.6521874 7.404979294 0.179332437 
10.18406471 
849.6225426 4.508143137 0.265722764 
4.095063966 
713.5660022 3.479005901 0.394100478 
3.892589762 
757.6219046 2.955278254 0.419146526 
3.220660652 




1039.773724 9.624692087 0.662995253 
  10.08619471   
789.6415841 3.525210168 0.781520977 
  3.35819505   
848.6139741 4.926367149 0.843283757 
  5.046528244   
845.6503385 3.272838889 0.872566889 
  3.375483166   
805.6547989 2.812182556 0.872566889 
  2.752888386   
      
GC vs. non-GC in HIV positive samples   
Mass (m/z) 
Average spectral 
counts P Value 
1105.431116 24.61210873 1.22509E-31 
  5.313585109 4.35763E-30 
1199.245457 17.67092282 1.27058E-24 
  50.91851233 1.27058E-24 
1032.988102 7.540316488 1.27058E-24 
  23.56449408 1.27058E-24 
944.884397 37.7799762 1.25578E-12 
  57.58455126 1.25578E-12 
788.7635164 9.003112793 1.35664E-12 
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